2 A2B, 0/A2B IgM AF647 0 T ,000 C3/AFP IgG Annexin V AF488 0 T ,000 PE 0 T ,000 APC 2 T ,000 FITC 2 T ,000 PE 2 T 60
|
|
|
- せせら はまもり
- 5 years ago
- Views:
Transcription
1 BD Biosciences *
2 2 A2B, 0/A2B IgM AF647 0 T ,000 C3/AFP IgG Annexin V AF488 0 T ,000 PE 0 T ,000 APC 2 T ,000 FITC 2 T ,000 PE 2 T ,000 Alphafetoprotein 0 T ,000 V40 0 T ,000 V00 0 T 60 44,000 ASGPR 8D7 IgG, κ PE 0 T ,000 B7-H4 MIH43 IgG, κ APC 0 T ,000 BV42 0 T ,000 PE 0 T ,000 0 T ,000 Purified 0 µg ,000 B220/CD4R RA3-6B2 Rat IgG, κ BV0 0 µg ,000 Bcl-2 Bcl-2/00 IgG Bcl-6, K2-9 IgG, κ AF647 0 T ,000 0 T ,000 Purified 0 µg 07 39,000 V40 0 T ,000 AF488 0 T ,000 AF647 0 T 62 40,000 0 T ,000 BV42 0 T ,000 PE 0 T ,000 0 T ,000 0 T ,000 0 T ,000 V40 0 T ,000 Blimp- E7 Rat IgG, κ AF647 0 µg ,000 BMI- P-3 IgG, κ BrdU 3D4 IgG, κ AF488 0 T ,000 AF647 0 T ,000 PE 0 T ,000 0 T ,000 PerCP 0 T ,000 0 T ,000 V40 0 µg ,000 BV0 0 T ,000 C3a Receptor hc3arz8 IgG, κ AF647 0 T ,000 Caspase-3, Active Form AF647 0 T ,000 C92-60 Rab, IgG FITC 2 T ,000 PE 2 T 60 2,000 V40 0 T ,000 CCL8/DC-CK AZN-CK8 IgG AF647 0 T ,000 CDa HI49 IgG, κ CDd APC 2 T 67 23,000 BV42 2 T ,000 BV0 2 T ,000 FITC 2 T ,000 PE 2 T 674 2,000 CDd42 IgG, κ BV0 2 T ,000 APC 2 T ,000 B Rat IgG, κ PE 2 T 677 2,000 BV42 0 µg ,000 BV0 0 µg ,000 FITC 0 µg 676,000 0 µg ,000 CD2 CD3 RPA-2.0 IgG, κ APC 0 T ,000 BUV39 2 T ,000 BV42 2 T ,000 FITC 2 T ,000 PE 2 T ,000 2 T ,000 0 T ,000, Rhe, FITC 0 T ,000, Rhe, Rhe, Cyno, Bab, Rhe, HIT3a SK7 UCHT IgG, κ IgG, κ APC 2 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 2 T ,000 2 T ,000 H7 2 T ,000 BUV39 2 T ,000 BV42 2 T ,000 BV60 2 T ,000 BV60 2 T ,000 BV786 2 T ,000 2 T ,000 AF700 2 µg ,000 APC 2 T ,000 BB 2 T ,900 BUV39 2 T ,000 BUV737 2 T ,000 BV42 2 T ,000 BV0 0 T ,000 BV60 2 T 638 3,000 BV7 2 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 2 T ,000 2 T ,000 0 T ,000 V40 30 T ,000 V00 2 T ,000 SP34 IgG, λ 3 PE 0 T ,000 FITC 0 T 66 3,000 SP34-2 IgG, λ AF488 0 T ,000 AF700 2 µg ,000 APC 0 T 797 3,000 0 T ,000 BUV39 0 T 647 4,000 BV42 0 T 62877,000 BV60 0 T ,000 BV60 0 T ,000 BV786 0 T ,000 PE 0 T ,000 0 T ,000 0 T ,000 PerCP 0 T 28 4,000 0 T 282 4,000 V40 30 T ,000 V00 2 T ,000 Rat F4 IgM, κ BV60 0 µg ,000 BV42 0 µg ,000 FITC 0 µg ,000
3 CD3e CD3 ε CD3 Molecular Complex CD4a CD4 Pig 4-2C Ar Ham IgG, κ APC 2 µg ,000 2 µg ,000 BUV39 0 µg 636 4,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 FITC 2 µg 6827,300 PE 2 µg ,000 Cy 2 µg ,600 2 µg 682 4,000 2 µg 600 6,000 PerCP 2 µg 6089,000 2 µg 608,000 00A2 Syr Ham IgG V40 2 µg ,800, κ 2 V00 2 µg ,800 BB23-8E6-8C8 IgG, κ 7A2 Rat IgG, κ Pig IgG, κ AF647 0 µg ,000 PE 0 µg ,000 0 µg ,000 0 µg ,000 AF700 0 µg ,00 0 µg ,000 BV42 0 µg ,000 BV60 0 µg ,000 BV786 0 µg ,000 PE 2 µg ,900 0 µg ,000 0 µg ,000 V40 0 µg ,000 0 µg ,000 0 µg ,000 Pig, Chick AF647 0 µg ,000 BNI3 IgG, κ BV786 0 T ,000 RPA-T4 IgG, κ AF700 2 µg ,000 APC 2 T ,000 2 T ,000 H7 2 T 602 3,000 BB 2 T ,900 BV42 2 T ,000 BV60 2 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 2 T ,000 2 T ,000 0 T ,000 0 T ,000 V40 30 T ,000 V00 2 T ,000 BUV39 2 T 632 3,000 BUV737 2 T ,000 BV0 2 T ,000 CD4, Rhe, Rhe, Cyno, Bab, Rhe, Rhe, Cyno, Bab, Rhe, Rat L200 IgG, κ AF700 0 T ,000 APC 0 T ,000 H7 0 T ,000 BB 0 T ,900 BUV39 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 BV60 0 T ,000 BV7 0 T ,000 BV786 0 T ,000 FITC 0 T ,000 PE 0 T ,000 0 T ,000 0 T ,000 PerCP 0 T ,000 0 T ,000 V40 0 T ,000 V00 0 T ,000 M-T477 IgG, κ PE 0 T ,000 FITC 0 T 66 3,000 GK. H29.9 RM4- OX-3 Rat IgG, κ Rat IgG, κ IgG, κ 2 µg ,000 H7 2 µg ,300 BUV39 0 µg ,000 BV42 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 BV786 0 µg ,000 FITC 2 µg ,000 PE 2 µg ,000 FITC 2 µg 683 3,900 PE 2 µg 6832,00 AF700 2 µg 602 6,200 APC 2 µg 609 4,000 BV0 0 µg ,000 BV60 0 µg 63 4,000 BV60 0 µg ,000 BV7 0 µg ,000 BV786 0 µg ,000 FITC 2 µg 683 4,600 PE 2 µg ,000 Cy 2 µg ,600 2 µg ,000 2 µg ,000 PerCP 2 µg ,000 2 µg 6 20,000 V40 2 µg ,800 V00 2 µg ,800 FITC 0 µg ,000 0 µg ,000 V40 0 µg ,000 OX-38 FITC 0 µg ,000 SK3 BV60 2 T ,000 BV7 2 T ,000 BV786 2 T ,000 2 T ,000 3
4 CD UCHT2 IgG, κ Rat IgG, κ CD7 M-T70 IgG, κ CD8, Rhe, HIT8a AF700 0 T 69 4,000 APC 2 T ,000 BV0 2 T ,000 BV7 0 T ,000 FITC 2 T ,000 PE 2 T ,000 V40 0 T 64 4,000 APC 2 µg 689 9,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 V40 0 µg ,200 AF700 0 T ,000 APC 0 T ,000 FITC 2 T ,000 PE 2 T ,000 0 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 2 T ,000 AF488 0 T ,000 AF700 2 µg ,000 AF700 0 T ,000 APC 0 T ,000 APC 2 T ,000, Rhe, 0 T ,000 BUV39 2 T ,000 BV42 2 T ,000, Rhe, BV0 0 T ,000 BV60 2 T ,000 BV7 2 T ,000 BV786 2 T ,000 FITC 0 T 708 3,000 RPA-T8 FITC 2 T ,000, Rhe, PE 0 T ,000 IgG, κ PE 2 T ,000, Rhe, Cy 2 T 623 3,000 2 T 69 27,000 0 T ,000 2 T ,000 0 T ,000, Rhe, V40 0 T ,000 V40 30 T ,000 V00 2 T ,000 2 T ,000 H7 2 T ,000, Rhe, H7 0 T ,000 SK BV60 2 T 64 3,000 V00 0 T ,000 Rhe, Cyno, Bab CD8a Rat IgG, κ V00 0 T 668 4,000 APC 2 µg ,000 2 µg ,800 H7 2 µg ,300 BB 2 µg ,800 BUV39 0 µg ,000 CD8a Rat IgG, κ BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg 632 4,000 BV60 0 µg ,000 BV7 0 µg ,000 BV786 0 µg ,000 FITC 2 µg ,700 PE 2 µg 609 8,000 Cy 2 µg ,600 2 µg ,000 2 µg ,900 PerCP 2 µg ,900 2 µg ,900 V40 2 µg ,800 V00 2 µg ,800 Pig IgG, κ AF647 0 µg ,000 Rat OX-8 IgG, κ FITC 0 µg ,000 AF647 0 µg 66 39,000 V40 0 µg ,000 CD8b Pig 29/33-2 IgG, κ PE 0 µg ,000 CD9 M-L3 IgG, κ CD0 CDa CDb HI0a IgG, κ 0 T ,000 V40 0 T ,000 BV0 0 T ,000 PE 2 T ,000 Cy 2 T ,000, Rhe, PE 0 T ,000, Rhe, HI IgG, κ 2D7 M7/4, APC 0 T ,000 BV42 2 T ,000 BV0 2 T ,000 PE 0 T 08 39,000 0 T ,000 Rat IgG, κ AF647 0 µg ,000 BV42 0 µg ,000 M/70 Rat IgG, κ Rat WT. IgA, κ BV0 0 µg ,000 APC 2 µg 6690,000 2 µg ,000 BB 2 µg 644 7,800 BUV39 0 µg 633 4,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg 630 4,000 BV60 0 µg ,000 BV7 0 µg ,000 FITC 2 µg ,700 PE 2 µg ,000 2 µg ,600 2 µg ,000 2 µg 64,000 V40 2 µg ,800 V00 2 µg ,700 APC 0 µg ,000 FITC 0 µg ,000 PE 0 µg 620 4,000 V40 0 µg ,000 CDb/c Rat OX-42 IgG, κ 0 µg ,000 FITC 0 µg ,000 4
5 CDb/Mac- CDc ICRF44 IgG, κ AF488 2 T ,000 APC 2 T 60 23,000 2 T ,000 BUV39 2 T ,000 BV0 0 T ,000 BV60 2 T ,000 PE 2 T 600 2,000 Cy 2 T ,000 2 T ,000 V40 30 T ,000, Rhe, PE 0 T ,000 B-ly6 IgG, κ HL3 Ar Ham IgG, CD3 WM IgG, κ CD4 M φ P9 IgG, κ, Rhe,, Dog, Rhe, Cyno ME2 IgG, κ AF700 0 T 632 4,000 APC 2 T ,000 BB 2 T ,00 BUV39 2 T ,000 BV0 0 T ,000 BV60 2 T ,000 BV60 2 T ,000 BV7 0 T ,000 PE 2 T ,000 Cy 2 T ,000 0 T ,000 V40 30 T ,000 AF700 0 µg ,00 λ 2 2 µg 69 9,000 BUV39 0 µg 0 µg 624 3, ,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 BV786 0 µg ,000 FITC 2 µg 604 7,00 PE 2 µg ,900 2 µg ,900 0 µg ,000 V40 0 µg ,200 APC 2 T ,000 PE 2 T ,000 0 T ,000 0 T ,000 2 T ,000 H7 2 T ,000 BUV39 2 T ,000 BV42 2 T ,000 BV0 0 T ,000 BV7 2 T ,000 2 T ,000 V40 30 T ,000 AF488 2 T ,000 AF700 2 µg ,000 APC 2 T ,000 APC 0 T ,000 H7 0 T ,000 CD4 CD, Rhe,, Dog ME2 IgG, κ BV60 2 T 640 3,000 BV60 2 T ,000 BV786 2 T ,000 FITC 2 T ,000, Rhe, FITC 0 T 73 3,000 Cyno, Dog PE 0 T 74 42,000, Rhe,, Dog, Rhe, Cyno, Dog, Rhe,, Dog, Rhe, Cyno PE 2 T ,000 0 T ,000 2 T ,000 2 µg 66 20,000 V40 0 T ,000 V00 2 T ,000 rmc-3 Rat IgG, κ HI98 IgM, κ APC 0 µg ,000 0 µg ,000 PE 2 µg 67 2,900 0 µg ,000 V40 0 µg ,200 APC 2 T ,000 FITC 2 T ,000 PE 2 T 67 2,000 0 T ,000 0 T ,000 V40 0 T ,000 V00 0 T 68 4,000 W6D3 IgG, κ BV60 2 T ,000 BV0 0 T 634 4,000 BV7 0 T ,000 CDs CSLEX IgM, κ BV42 0 T ,000 BV0 0 T ,000 CD6/CD32 2.4G2 Rat IgG, κ CD6, Rhe,, Rhe, 3G8 IgG, κ BV7 0 T ,000 0 µg ,000 BV42 0 µg ,000 BV60 0 µg ,000 PE 0 µg ,200 0 µg ,200 0 µg ,000 V40 0 µg ,200 AF647 2 T ,000 AF700 0 T ,000 APC 0 T ,000 H7 0 T ,000 H7 2 T ,000 2 T ,000 BV42 2 T ,000 BUV39 2 T ,000 BV0 2 T ,000 BV60 2 T ,000 BV60 2 T ,000 BV7 0 T ,000, Rhe, BV786 2 T ,000 FITC 2 T ,000, Rhe, FITC 0 T 668 3,000 0 T ,000 PE 0 T ,000
6 CD6 CD8 CD9 3G8 IgG, κ PE 2 T ,000 Cy 2 T ,000 2 T ,000 2 T ,000 0 T ,000 V40 30 T ,000, Rhe, V40 0 T ,000 V00 2 T ,000 B73., Rhe, Cyno, Pig, Rab APC 0 T ,000 H7 0 T ,000 V40 0 T , IgG, κ FITC 0 T 76 3,000 C7/6 Rat IgG, κ BV42 0 µg ,000 HIB9 SJ2C IgG, κ D3 Rat IgG, κ AF700 2 µg ,000 APC 2 T ,000 H7 0 T ,000 BB 2 T ,900 BV42 2 T ,000 FITC 2 T ,000 PE 2 T 674 2,000 Cy 2 T ,000 2 T ,000 0 T ,000 0 T ,000 V40 30 T ,000 V00 2 T 62 30,000 2 T ,000 H7 2 T ,000 BUV39 2 T 63 3,000 BUV737 2 T ,000 BV0 2 T ,000 BV60 2 T ,000 BV60 2 T ,000 BV7 2 T ,000 BV786 2 T ,000 2 T ,000 APC 2 µg ,800 2 µg ,800 H7 2 µg ,300 BB 2 µg ,800 BUV39 0 µg 637 4,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 BV60 0 µg ,000 BV7 0 µg 637 4,000 BV786 0 µg ,000 FITC 2 µg ,000 PE 2 µg ,900 2 µg ,600 2 µg ,900 2 µg 63 20,900 V40 2 µg ,800 CD20 CD2, Rhe, 2H7 IgG, κ AF700 0 T ,000 APC 2 T ,000 H7 0 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 2 T ,000 2 T ,000 0 T ,000 0 T ,000 H7 0 T ,000 BV0 0 T ,000 BV7 0 T ,000 FITC 0 T ,000 PE 0 T ,000 0 T ,000, Rhe, BUV39 2 T ,000 Cyno, Bov BV60 2 T ,000, Rhe, L27 IgG, κ V40 0 T ,000, Rhe,, Rhe,, Pig B-ly4 IgG, κ APC 0 T ,000 APC 2 T ,000 BV7 0 T ,000 PE 0 T ,000 PE 2 T ,000 0 T ,000 V40 0 T ,000, Rhe, V40 0 T ,000 CD2/CD3 7G6 Rat IgG, κ APC 2 µg ,000 BV42 0 µg ,000 BV0 0 µg 637 4,000 BV60 0 µg ,000 CD22 HIB22 IgG, κ FITC 2 T 677 2,000 CD23 CD24 M-L233 IgG, κ B3B4 Rat IgG, κ ML IgG, κ M/69 Rat IgG, κ PE 2 T ,000 0 T ,000 0 T ,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 BV786 0 µg ,000 PE 2 µg ,000 AF647 0 T ,000 BV0 0 T ,000 BV7 2 T ,000 FITC 2 T ,000 PE 2 T ,000 0 T ,000 0 T ,000 BV42 0 µg ,000 BV0 0 µg 63 4,000 BV60 0 µg ,000 BV60 0 µg 634 4,000 BV7 0 µg ,000 PE 2 µg ,300 0 µg ,00 Rat HIS0 IgM, κ PE 0 µg ,000 6
7 CD2 CD27 2A3 M-A2 IgG, κ BB 2 T 64468,700 BUV737 2 T ,000 BV60 2 T ,000 BV7 0 T 639 4,000 AF700 0 T ,000 APC 2 T ,000, Rhe, APC 0 T ,000 2 T ,000 H7 2 T ,000 BV42 2 T ,000 BV0 2 T 633 3,000 BV60 2 T ,000 BV786 2 T ,000 FITC 2 T ,000 PE 2 T ,000, Rhe, Cy, Rhe, PE 0 T ,000 0 T ,000 2 T ,000 2 T ,000 0 T ,000 0 T ,000 V40 30 T ,000 7D4 Rat IgM, κ AF647 0 µg ,000 FITC 2 µg ,000 PC6 Rat IgG, λ APC 2 µg ,000 2 µg ,000 BB 2 µg ,900 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 BV786 0 µg ,000 PE 2 µg 606 2,000 2 µg ,600 2 µg ,000 2 µg 62 20,000 V40 0 µg ,200 Rat OX-39 IgG, κ FITC 0 µg ,000 L28 IgG, κ BUV39 2 T ,000 BUV737 2 T ,000 BV0 2 T ,000 BV60 2 T ,000 BV60 2 T ,000 BV7 0 T ,000 BV786 2 T ,000 AF700 0 T ,000 APC 2 T ,000, Rhe, APC 0 T ,000 H7 2 T ,000 BV42 2 T ,000 FITC 2 T ,000, Rhe, M-T27 FITC 0 T ,000 PE 2 T ,000, Rhe, PE 0 T ,000 2 T ,000 0 T ,000 0 T ,000 CD27 CD28 CD29 CD3 V40 30 T ,000, Rhe, M-T27 IgG, κ V40 0 T ,000 V00 2 T ,000 APC 0 µg ,00 V40 0 µg ,200 LG.3A0 Ar Ham IgG, κ BV0 0 µg ,000, Rat BV60 0 µg ,000 PE 2 µg 678 2,700 APC 2 T ,000, Rhe, APC 0 T ,000 H7 0 T ,000 BV0 0 T ,000 BV7 0 T 633 4,000 FITC 2 T ,000, Rhe, FITC 0 T 662 3,000 PE 2 T ,000, Rhe, CD28.2 IgG, κ PE 0 T ,000, Rhe, Cy 2 T ,000 2 T ,000 0 T ,000 0 T ,000 V40 0 T ,000, Rhe, V40 0 T , Syr Ham IgG 2, λ, Rhe, MAR4 IgG, κ BV42 0 µg ,000 PE 2 µg ,700 APC 2 T ,000 BV0 2 T 634 3,000 PE 0 T ,000 PE 2 T 679 2,000, Rat Ha2/ Ar Ham IgM, κ Pig NaM60- A3 BV42 0 µg 643 4,000 FITC 0 µg ,000 PE 0 µg ,000 V40 0 µg 62 38,000 IgG, κ AF647 0 µg ,000 Rat Ha2/ Ar Ham IgM, κ AF647 0 µg ,000 WM9 IgG, κ AF647 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T 628 4,000 FITC 2 T ,000, Rhe, FITC 0 T 708 3, MEC 3.3 Rat IgG, κ PE 2 T ,000 V40 0 T ,000 AF488 0 µg ,000 AF647 0 µg ,000 0 µg ,00 BV42 0 µg ,000 APC 2 µg 684 6,000 BV42 0 µg ,000 BV0 0 µg ,000 FITC 2 µg 683 6,700 PE 2 µg ,400 0 µg ,000 CD32 Rat D34-48 IgG, κ PE 0 µg ,000 7
8 CD33 CD34 HIM3-4 WM3 8, Rhe, 63 IgG, κ IgG, κ FITC 2 T ,000 AF700 0 T 660 4,000 APC 2 T ,000 BV42 0 T ,000 BV0 0 T ,000 BV7 0 T 637 4,000 PE 2 T 686 2,000 V40 0 T 67 44,000 AF700 0 T ,000 APC 2 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 2 T ,000 0 T ,000 APC 0 T ,000 PE 0 T ,00 0 T ,000 RAM34 Rat IgG, κ AF700 0 µg ,00 AF647 2 µg ,000 CD36 CB38 IgM, κ CD37 M-B37 IgG, κ CD38 CD40 HB7 HIT2 IgG, κ BV42 0 µg ,000 APC 2 T ,000 FITC 2 T ,000 PE 2 T 682 2,000 0 T ,000 V40 0 T 63 40,000 AF647 0 T ,000 PE 0 T ,000 0 T ,000 V40 0 T ,000 BUV39 2 T ,000 BV60 2 T ,000 AF700 0 T ,000 APC 2 T ,000 BB 2 T ,200 BV42 2 T ,000 BV0 0 T 632 4,000 FITC 2 T ,000 PE 2 T ,000 Cy 2 T ,000 2 T ,000 0 T ,000 2 µg ,000 V40 0 T ,000 90/CD38 Rat IgG, κ BV42 0 µg ,000 C3 IgG, κ AF700 0 T ,000 APC 2 T ,000 H7 0 T 62 40,000 BV42 0 T ,000 BV0 0 T ,000 BV7 0 T ,000 FITC 2 T ,000, Rhe, FITC 0 T ,000 PE 0 T ,000 PE 2 T ,000 0 T 62 40,000 V40 0 T ,000 CD40 CD4 MWReg30 Rat IgG, κ CD4a 3/23 Rat IgG, κ PE 2 µg 6846,000 BV42 0 µg ,000 HM40-3 Ar Ham IgM, κ AF647 0 µg ,000 BV42 0 µg ,000 BV60 0 µg ,000 FITC 0 µg ,000 PE 2 µg 680 3,000 BUV39 0 µg ,000 APC 2 T ,000 H7 0 T ,000 BV0 0 T ,000 FITC 2 T 68 23,000, Rhe, HIP8 IgG, κ FITC 0 T ,000 PE 0 T ,000 PE 2 T ,000, Rhe, 0 T ,000 V40 0 T ,000 CD4b HIP2 IgG, κ BV42 0 T ,000 3 CD4 ALMA.6 IgG, κ PE 2 T ,000 CD4 HIP IgG, κ FITC 2 T 68 23,000 PE 2 T 684 2,000 CD43 CD44 CD4 G0 IgG, κ FITC 2 T ,000 S7 Rat IgG, κ APC 0 µg ,000 BV42 0 µg ,000 G44-26 IgG, κ IM7 Rat IgG, κ 2D HI30 IgG, κ PE 2 µg ,900 AF700 0 T ,000 APC 2 T ,000 H7 0 T ,000 BV0 0 T ,000 FITC 2 T ,000 PE 2 T 688 2,000 0 T ,000 0 T ,000 V40 0 T ,000 AF700 0 µg ,00 APC 2 µg ,000 0 µg ,00 BV42 0 µg ,000 BV0 0 µg 634 4,000 BV60 0 µg ,000 BV7 0 µg ,000 BV786 0 µg ,000 PE 2 µg ,000 Cy 2 µg 686,000 0 µg ,00 0 µg ,00 V40 2 µg ,800 V00 2 µg ,800 Cy 7 2 T ,000 H7 2 T ,000 AF700 0 T ,000 APC 2 T ,000 BUV39 2 T ,000 BV42 2 T ,000 BV60 2 T ,000 FITC 2 T ,000 PE 2 T ,000 2 T ,000 8
9 CD4 CD4R HI30 IgG, κ 30-F Rat IgG, κ Rat OX- IgG, κ Rhe, Cyno, Bab D IgG, κ Cy 2 T ,000 2 T 609 2,000 V40 30 T ,000 V00 2 T ,000 AF700 0 µg 600 2,00 APC 2 µg 608 3,000 BUV39 0 µg 2 µg , ,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 BV786 0 µg ,000 FITC 2 µg ,000 PE 2 µg ,000 Cy 2 µg ,000 2 µg ,000 PerCP 2 µg ,000 2 µg ,000 V40 0 µg ,200 V00 0 µg ,200 0 µg ,000 FITC 0 µg ,000 0 µg ,000 V40 0 µg ,000 AF700 0 T ,000 APC 0 T ,000 BUV39 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 BV786 0 T ,000 FITC 0 T ,000 PE 0 T ,300 0 T ,000 0 T ,000 PerCP 0 T 84 43,000 V40 0 T 629 4,000 V00 0 T ,000 RA3-6B2 Rat IgG, κ V40 2 µg ,800 Rat HIS24 IgG, κ FITC 0 µg ,000 CD4R/B220 RA3-6B2 Rat IgG, κ BV7 0 µg ,000 APC 2 µg 6880,000 2 µg 602 6,000 BUV39 0 µg ,000 BV42 0 µg ,000 BV60 0 µg ,000 BV60 0 µg ,000 BV786 0 µg ,000 FITC 2 µg 6877,300 PE 2 µg ,000 Cy 2 µg ,600 2 µg ,000 2 µg 688 6,000 CD4R/B220 RA3-6B2 Rat IgG, κ CD4RA HI00 IgG, κ, Rhe, Rat H9 OX-33 IgG, κ PerCP 2 µg ,000 2 µg 60,000 V00 2 µg ,00 AF700 0 T ,000 APC 2 T ,000 H7 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 BV60 0 T ,000 BV7 0 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 2 T ,000 2 T ,000 0 T ,000 V40 30 T ,000 V00 0 T ,000 APC 0 T ,000 H7 0 T ,000 FITC 0 T ,000 PE 0 T ,000 0 T ,000 V40 0 T ,000 0 µg ,000 FITC 0 µg ,000 V40 0 µg ,000 CD4RB 6A Rat IgG, κ BV42 0 µg ,000 CD4RO UCHL IgG, κ CD4. A20 IgG, κ AF700 0 T 636 4,000 APC 2 T ,000 H7 0 T ,000 BUV39 2 T ,000 BV42 2 T ,000 BV60 2 T ,000 BV60 2 T ,000 BV7 2 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 2 T ,000 2 T ,000 0 T ,000 0 T ,000 AF700 0 µg 623 2,00 APC 2 µg ,000 0 µg ,000 BV42 0 µg ,000 BV60 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 PE 2 µg ,000 0 µg ,000 0 µg ,000 V40 0 µg ,200 9
10 CD IgG, κ CD47 B6H2 IgG, κ BV786 0 µg ,000 AF700 0 µg ,00 APC 2 µg 687 2,000 0 µg ,300 BV42 0 µg ,000 BV60 0 µg 630 4,000 BV7 0 µg ,000 0 µg ,900 2 µg ,000 V40 0 µg ,200 V00 2 µg ,700 AF647 0 T ,000 0 T ,000 V40 0 T ,000 miap30 Rat IgG, κ AF647 0 µg ,000 PE 0 µg ,000 CD48 HM48- CD49a Ha3/8 Ar Ham IgG, λ 3 Ar Ham IgG 2, λ CD49b/ Pan-NK Cells DX Rat IgM, κ APC 0 µg ,00 0 µg ,000 BV42 0 µg ,000 BV0 0 µg ,000 PE 0 µg ,000 0 µg ,000 AF647 0 µg 623 2,000 PE 0 µg 62 37,000 APC 0 µg ,000 BV42 0 µg ,000 FITC 2 µg 6067,300 PE 2 µg ,400 V40 0 µg ,00 CD49b, Rat Ha/29 Ar Ham IgG, λ FITC 0 µg ,000 2 CD49d, Rhe,, Dog, Bov,Sheep, Cat, Hs APC 2 T ,000, Rhe, BV0 0 T ,000, Rhe,, BV7 0 T ,000 Dog, Bov 9F0 IgG, κ, Rhe, PE 2 T ,000, Dog, Bov,Sheep, PE 0 T ,000 Cat, Hs, Rhe,, Dog, Bov 0 T ,000 0 T ,000 CD49e IIA IgG, κ AF647 0 T 6378 CD49f,, Pig, Dog GoH3 Rat IgG, κ CD2 4C8 IgG 3, κ AF647 2 T ,000 BV42 2 T ,000 BV0 0 T ,000 BV60 2 T ,000 FITC 2 T ,000 PE 2 T ,000 2 T ,000 2 T ,000 AF647 0 T ,000 H7 0 T ,000 BV0 0 T ,000 PE 0 T ,000 CD4 3E2 Ar Ham IgG, κ APC 0 µg ,300 BV0 0 µg ,000 CD IA0 IgG, κ FITC 2 T ,000 PE 2 T 690 2,000 CD6 B9 IgG, κ NCAM6.2 IgG, κ AF488 2 T ,000 AF700 2 µg ,000 BB 2 T ,400 PE 2 T ,000 Cy 2 T ,000 2 T ,000 2 T ,000 0 T ,000 V40 30 T ,000 BUV39 2 T 63 3,000 BV42 2 T ,000 BV0 0 T ,000 BV60 2 T ,000 BV7 0 T ,000, Rhe, MY3 IgG, κ PE 0 T ,000 CD7 NK- IgM, κ APC 0 T ,000 BV42 0 T ,000 BV60 0 T ,000 FITC 2 T ,000 CD8, Dog C3 AICD8.6 IgG, κ AF647 0 T ,000 FITC 2 T ,000 CD9 CD6 CD62L FITC 2 T ,000 p282 H9 IgG, κ PE 2 T ,000, Rhe, PE 0 T 74 36,000 Rat TH9 IgG, κ PE 0 µg ,000 APC 0 µg ,000, Dog V40 0 µg ,000 FITC 2 T ,000, Rhe, VI-PL2 IgG, κ FITC 0 T ,000, Rhe,, PE 2 T 692 2,000 Bov, Rat 2C9.G2 Ar Ham IgG, κ BV42 0 µg ,000 AF647 0 µg ,000 PE 2 µg 690 3,400 Rat F IgG, κ FITC 0 µg ,000 DREG-6 IgG, κ MEL-4 Rat IgG, κ APC 2 T ,000 BV0 0 T ,000 BV60 2 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 2 T ,000 2 T 69 27,000 V40 30 T ,000 AF700 0 µg ,00 APC 2 µg 699 2,000 0 µg 604 2,00 BV42 0 µg ,000 BV0 0 µg 637 4,000 BV60 0 µg ,000 PE 2 µg 698 2,000 0 µg ,000 0 µg ,000 V40 0 µg ,200 0
11 CD62P CD63, Rhe, AK-4 AC.2 IgG, κ APC 2 T ,000 BV42 2 T ,000 BV60 2 T ,000 BV786 2 T ,000 FITC 2 T ,000 PE 2 T ,000 FITC 0 T ,000 PE 0 T 06 38,00 RB40.34 Rat IgG, λ AF647 0 µg ,000 BV60 0 µg ,000 AF647 0 T ,000 FITC 2 T ,000, Rhe, FITC 0 T ,000 HC6 IgG, κ PE 0 T ,000 PE 2 T 692 2,000 CD64 0. IgG, κ CD66b G0F IgM, κ 0 T ,000 V40 0 T ,000 AF700 0 T ,000 APC 0 T ,000 H7 0 T ,000 BV42 0 T ,000 FITC 2 T ,000 PE 2 T ,000 0 T 69 40,000 0 T ,000 V40 0 T ,000 AF647 0 T ,000 FITC 2 T ,000 PE 0 T ,000 0 T ,000 V40 0 T ,000 CD68 Y/82A IgG, κ AF647 0 T 62 46,000 FITC 0 T ,000 CD69 FN0 IgG, κ AF700 0 T ,000 APC 2 T ,000, Rhe, APC 0 T ,000, Rhe, 2 T ,000 H7 0 T ,000 BV42 0 T ,000 FITC 0 T ,000 FITC 2 T ,000 PE 2 T ,000, Rhe, PE 0 T ,000 Rhe, Cyno, Bab, Rhe, H.2F3 Ar Ham IgG, λ 3 0 T ,000 0 T ,000 0 T ,000 2 T ,000 V40 0 T ,000 AF700 0 µg ,00 APC 0 µg ,000 0 µg ,00 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 FITC 2 µg ,300 CD69 H.2F3 CD70 CD7 CD73 CD79a CD79b CD80 CD8 CD83 Ar Ham IgG, λ 3 PE 2 µg ,400 2 µg ,000 2 µg ,000 V40 0 µg ,200 Ki-24 IgG, κ PE 2 T 693 2,000 3 FR70 Rat IgG, κ BV42 0 µg ,000 M-A72 IgG, κ C2 Rat IgG, κ AD2 IgG, κ APC 2 T ,000 BV42 0 T ,000 BV7 0 T ,000 BV786 0 T ,000 FITC 2 T ,000 PE 2 T ,000 AF647 0 µg ,000 BV42 0 µg ,000 BV0 0 µg 632 4,000 BV60 0 µg ,000 PE 2 µg ,000 BV42 2 T ,000 PE 2 T 604 2,000 0 T ,000 0 T ,000 V40 0 T 62 47,000 TY/23 Rat IgG, κ AF647 0 µg ,00 AF488 0 µg 64 37,00 V40 0 µg ,200 HM47 IgG, BV42 0 T ,000 κ, PE 2 T ,000 CB3- IgG, κ PE 2 T ,000 HM79b Ar Ham IgG 2, λ L307.4 IgG, κ 6-0A Ar Ham IgG 2, κ, Dog, Rab, Rhe, Cyno FITC 0 µg ,400 AF700 0 T 633 4,000 H7 0 T 634 4,000 BV0 0 T ,000 FITC 2 T ,000 PE 2 T ,000 0 T 63 40,000 V40 30 T ,000 BV42 0 µg 626 4,000 BV60 0 µg ,000 PE 2 µg 69 2,000 0 µg ,600 V40 0 µg ,200 JS-8 IgG, κ FITC 2 T ,000 APC 2 T ,000 HBe IgG, κ Michel-9 Rat IgG, κ PE 2 T ,000 APC 2 T ,000 BV42 0 T ,000 BV0 0 T ,000 FITC 2 T ,000 FITC 0 T 603 3,000 PE 0 T ,000 PE 2 T 699 2,000 0 T ,000 0 T ,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000
12 CD86 CD90, Rhe, AF700 0 T 624 4,000 APC 2 T ,000 BV42 2 T ,000 BV0 2 T ,000 BV60 2 T 634 3,000 BV7 0 T 638 4,000 FITC 2 T , FUN- IgG, κ, Rhe, FITC 0 T ,000 PE 0 T ,000 GL Rat IgG, κ PE 2 T ,000 0 T ,000 0 T ,000 V40 30 T ,000 AF700 0 µg 608 2,00 APC 2 µg ,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg 630 4,000 PE 2 µg ,000 0 µg ,000 V40 2 µg ,800 Rat 24F IgG, κ FITC 0 µg ,000, Rhe,, Pig, Dog, Rhe,, Pig, Dog E0 IgG, κ CD90., Rat OX-7 IgG, κ CD Rat IgG, κ CD93 Early B Lineage AA4. Rat IgG, κ CD9, Rhe,, Rhe,, Pig, Dog DX2 IgG, κ APC 2 µg ,000 FITC 2 µg ,000 BV0 0 T ,000 BV60 2 T ,000 PE 2 µg ,000 Cy 2 µg ,000 0 T 68 40,000 0 T 67 40,000 APC 0 µg ,300 0 µg 640 3,200 BV42 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 FITC 0 µg ,400 0 µg ,200 V40 0 µg ,200 APC 2 µg 6974,000 0 µg 664 3,200 BV60 0 µg ,000 0 µg ,00 V40 0 µg ,200 V00 0 µg ,000 BV42 0 µg ,000 BV60 0 µg ,000 0 µg ,000 V40 0 T ,000 APC 2 T ,000 BV7 0 T ,000 FITC 2 T ,000 FITC 0 T ,000 PE 2 T ,000 PE 0 T ,000 Cy 2 T ,000 CD9, Rhe, Rhe, Cyno, Bab DX2 Jo2 IgG, κ Ar Ham IgG 2, λ 2 0 T ,000 0 T ,000 0 T 66 40,000 V40 0 T ,000 AF647 0 µg ,000 BV42 0 µg ,000 BV0 0 µg ,000 PE 2 µg ,900 DX2 IgG, κ BV42 0 T ,000 CD96 6F9 IgG, κ BV7 0 T ,000 CD99 TÜ2 IgG, κ FITC 2 T ,000 CD03 CD0 CD06 Ber-ACT8 IgG, κ M290 Rat IgG, κ 266 IgG, κ BUV39 0 T ,000 BV7 0 T ,000 FITC 2 T ,000 BV42 0 T ,000 APC 0 µg ,000 BV42 0 µg ,000 BV0 0 µg ,000 PE 2 µg ,000 0 µg ,000 AF647 0 T ,000 APC 0 T ,000 BUV39 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 BV60 0 T ,000 0 T ,000 V40 0 T ,000 MHN4-2 AF647 0 T MJ7/8 Rat IgG, κ -0C9 IgG, κ 429 MVCAM. A AF647 0 µg ,00 BV42 0 µg ,000 PE 0 µg ,00 0 µg ,000 BV60 0 T ,000 PE 2 T ,000 0 T ,000 Rat IgG, κ PE 0 µg 663 9,000 AF647 0 µg 662 2,00 V40 0 µg 66 34,200 CD07A H4A3 IgG, κ AF647 0 T ,000 CD07a H4A3 IgG, κ D4B Rat IgG, κ AF700 0 T ,000 APC 0 T ,000 H7 0 T ,000 BB 0 T ,00 BV42 0 T ,000 BV0 0 T ,000 BV786 0 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 0 T ,000 2 T ,000 0 T ,000 V40 0 T ,000 APC 0 µg ,00 FITC 2 µg ,700 0 µg ,000 V40 0 µg ,200 2
13 CD07b H4B4 IgG, κ FITC 2 T ,000 CD6 CD7 hgmcsfr- M 04D2 YB.B8 IgG, κ BV60 0 µg ,000 BV42 0 µg ,000 IgG, κ 2B8 Rat IgG, κ BV60 0 T ,000 APC 2 µg 68 20,000 BV42 2 T ,000 PE 2 µg ,000 0 T ,000 0 T ,000 APC 2 µg ,000 H7 2 µg ,300 BUV39 0 µg 640 4,000 BV42 0 µg ,000 BV60 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 BV786 0 µg ,000 FITC 0 µg 6680,000 PE 2 µg 607 0,700 0 µg ,200 2 µg 668 6,000 0 µg ,000 V40 0 µg ,200 CD20b htnfr-m Rat IgG, κ AF647 0 T ,000 CD 3F Rat IgG, κ AF647 0 µg CD 4E2 Rat IgG BV42 0 µg ,000 CD22 CD23 Mik- β 3 IgG, κ BV42 0 T ,000 BV0 0 T ,000, Rhe, Mik- β 2 IgG, κ PE 0 T ,000 TM-Beta Rat IgG, κ FITC 0 µg ,000 BV42 0 µg ,000 7G3 IgG, κ 9F IgG, κ BUV39 0 T 649 4,000 BV42 0 T ,000 BV60 0 T ,000 BV60 0 T ,000 BV786 0 T ,000 FITC 2 T ,000 PE 2 µg 608 2,000 0 T ,000 0 T ,000 2 T ,000 AF647 0 T ,000 BV42 0 T 627 4,000 BV0 0 T ,000 BV7 0 T 636 4,000 PE 2 µg 600 2,000 Cy 2 T ,000 CD24 mil4r-m Rat IgG, κ BV42 0 µg ,000 PE 2 µg ,900 CD26 M IgG, κ APC 0 T ,000 PE 2 T ,000 CD27 HIL- 7R-M2 IgG, κ AF647 2 T ,000 BUV737 0 T ,000 BV42 2 T ,000 BV0 0 T ,000 BV60 0 T ,000 BV60 0 T ,000 BV7 0 T 636 4,000 BV786 0 T ,000 FITC 2 T ,000 CD27 CD32 HIL- 7R-M2 IgG, κ SB/99 Rat IgG, κ PE 2 µg ,000 0 T ,000 0 T ,000 0 T 60 46,000 V40 0 T ,000 AF488 0 µg 633 2,00 BV42 0 µg ,000 BV0 0 µg ,000 BV786 0 µg ,000 0 µg ,200 0 µg ,000 V40 0 µg ,200 AG84 IgG, κ BV7 0 T ,000 BV42 0 T ,000 TUGh4 Rat IgG, κ CD34 ACT3 IgG, κ CD3 A2F0. Rat IgG, κ CD37 4B4- IgG, κ CD38 CD40a MI IgG, κ 28-2 Rat IgG, κ α R IgG, κ PE 2 µg ,000 AF647 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 0 T ,000 APC 0 T ,000 BV60 0 T ,000 BV7 0 T ,000 PE 2 T ,000 0 T ,000 0 T ,000 APC 0 µg ,000 BV42 0 µg ,000 PE 2 µg ,700 0 µg ,200 APC 2 T ,000 BV42 0 T ,000 BV60 0 T ,000 PE 2 T 670 2,000 AF647 0 T ,000 BUV737 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 BV7 0 T ,000 FITC 2 T ,000 PE 2 T ,000 V40 0 T ,000 APC 2 µg ,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 PE 2 µg ,000 BV60 0 µg ,000 AF647 0 T ,000 BV42 0 T ,000 0 T ,000 APA Rat IgG, κ APC 0 µg ,00 CD40A APA Rat IgG, κ BV42 0 µg ,000 PE 0 µg ,000 0 µg ,200 3
14 BV42 0 T ,000 CD40b 28D4 IgG, κ 0 T ,000 CD4 A4 IgG, κ BV0 0 T ,000 BV7 0 T 63 4,000 CD42 HTF- IgG, κ PE 2 T 673 2,000 CD44 CD46 CD47 CD0 CD2 CD4-7H IgG, κ AF647 0 T ,000 FITC 2 T ,000 PE 2 T ,000 0 T ,000 V40 0 T ,000 D4. Rat IgG, κ BV42 0 µg ,000 AF647 0 µg ,00 PH2 IgG, κ ME-9F Rat IgG, κ HIM6 IgG, κ RL73 Rat IgG, κ PE 0 µg ,200 AF647 0 T ,000 BV0 0 T 632 4,000 BV7 0 T ,000 PE 2 T ,000 0 T ,000 0 T ,000 V40 0 T ,000 AF488 0 µg ,000 AF647 0 µg ,400 0 µg ,00 V40 0 µg ,700 AF647 0 T 62 46,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 PE 0 T ,000 0 T ,000 0 T 624 0,000 BV42 0 µg ,000 PE 0 µg ,200 0 µg ,000 A2 IgG, κ BV42 0 T ,000 Q Rat IgG, κ BV42 0 µg 628 4,000 AF647 0 µg ,00 TC- 2F2.2 PE 0 µg 626 3,200 Rat IgG, λ AF647 0 µg ,00 APC 2 T ,000 BV42 0 T ,000 BV786 0 T ,000 PE 2 T ,000, Rhe, BNI3 IgG, κ PE 0 T ,000 UC0-4F0-, Rhe, TRAP IgG, κ Cy 0 T ,000 2 T ,000 Ar Ham IgG, κ PE 2 µg 678 2,900 APC 2 T ,000 FITC 2 T ,000 FITC 0 T ,000 PE 2 T ,000 PE 0 T ,000 Cy 2 T ,000 MR Ar Ham IgG, κ PE 2 µg 679 2,000 3 CD8a HP-3E4 IgM, κ BV7 0 T ,000 CD8b CH-L IgG, κ PE 2 T ,000 CD60 CNX46-3 Rat IgG, κ 0 µg 622 3,200 CD6 DX2 IgG, κ BV42 0 T 626 4,000 APC 2 T ,000 BV0 0 T ,000 CD6a Rat 0/78 IgG, κ FITC 0 µg ,000 CD62 KPL- IgG, κ AF647 0 T ,000 2PH Rat IgG, κ BV42 0 µg ,000 AF647 0 µg ,00 CD63 GHI/6 IgG, κ BV0 0 µg ,000 AF647 0 T ,000 BV42 0 T ,000 FITC 0 T ,000 PE 2 T ,000 0 T ,000 CD64 N6B6 IgG, κ 0 T ,000 AF647 0 T ,000 CD66 3A6 IgG, κ BV42 0 T ,000 PE 2 T ,000 0 T 623 0,000 CD77 MEM-66 IgG, κ BV42 0 T ,000 CD83 CD84 C6/CXCR3 IgG, κ AF488 2 µg ,000 AF700 0 T ,000 APC 2 T ,000, Rhe, APC 0 T ,000 BV42 0 T 628 4,000, Rhe, CXCR3-73 Ar Ham IgG 2G IgG, κ BV60 0 T ,000 BV7 0 T 636 4,000 PE 0 T ,000 PE 2 T ,000 Cy 0 T ,000 2 T 673 2,000 0 T ,000 0 T ,000 APC 0 µg ,000 BV42 0 µg ,000 APC 2 T ,000 BV42 0 T ,000, Rhe, BUV39 0 T ,000 PE 0 T 74 4,000, Rhe, 2B/ CXCR4 Rat IgG, κ PE 2 T ,000 Cy 0 T ,000 2 T ,000 0 T ,000 0 T ,000 BV42 0 µg ,000 BV0 0 µg ,000 FITC 2 µg 673 7,00 PE 2 µg ,900 V40 0 µg ,200 4
15 CD8 CXCR 2G8 Rat IgG APC 0 µg ,200 BUV39 0 µg ,000 BV42 0 µg ,000 BV60 0 µg ,000 FITC 2 µg ,00 PE 2 µg ,000 0 µg ,000 0 µg ,00 0 µg ,000 CD92 CCR IgG, κ AF647 2 T ,000 CD93 CCR3 CD94 CCR4 CD9 CCR CD96 CCR6 E8 IgG, κ G IgG, κ Rhe, Cyno 2D7/CCR 3A9 IgG, κ AF647 2 µg ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 PE 2 µg ,000 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 PE 2 µg 60 2,000 2 µg ,000 0 T ,000 V40 0 µg ,000 APC 2 T ,000 2 T ,000 BV42 0 T ,000 BV60 0 T ,000 BV7 0 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 0 T ,000 2 T 670 2,000 2 T ,000 V40 0 T ,000 APC 0 T ,000 PE 2 T ,000, Rhe, Cyno A9 IgG, κ PE 0 T ,000 0 T ,000 AF647 2 T 67 29,000 APC 0 T ,000 BV42 0 T 62 4,000 BV0 0 T ,000 BV60 0 T ,000, Rhe, BV60 0 T ,000 BV7 0 T ,000, Rhe, Cyno, Rhe, BV786 0 T ,000 PE 2 µg 609 2,000 PE 0 T ,000 0 T ,000 2 T ,000 0 T , Rat IgG AF647 2 µg 673 2,900 CD97 CCR7 CD99 CCR9 CD IgG 3D2 Rat IgG, κ 4B2 Rat IgG 209 IgG MRC OX-04 IgG, κ CD203c NP4D6 IgG, κ CD206 CD209 DCN46 IgG, κ CD22 H7 IgG, κ AF700 0 T 643 4,000 BUV39 0 T ,000 BV42 0 T 62 4,000 BV7 0 T ,000 0 T ,000 0 T ,000 V40 30 T ,000 AF647 2 T ,000 BV0 0 T ,000 BV60 0 T 637 4,000 BV60 0 T ,000 BV7 0 T ,000 BV786 0 T ,000 FITC 2 T ,000 PE 2 T ,000 2 T ,000 BV42 0 µg ,000 0 µg ,000 AF488 0 µg ,000 PE 0 µg ,000 BV0 0 T ,000 BV60 0 T ,000 PE 2 T ,000 0 T ,000 0 T ,000 V40 0 T ,000 APC 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 PE 0 T , IgG, κ APC 2 T ,000 DCN46 IgG, κ BV42 0 T ,000 FITC 2 T ,000 PE 2 T 676 2,000 2 T ,000 V40 0 T ,000 BV42 0 T ,000 PE 2 T ,000 0 T ,000 CD223 C9B7W Rat IgG, κ BV7 0 µg ,000 CD23a GA-R2 HIR2 IgG, κ APC 2 µg ,000 BUV39 0 T ,000 BV42 0 T ,000 FITC 2 µg ,000 PE 2 µg 60 2,000 Cy 2 µg ,000 0 T ,000 CD238 BRIC 203 IgG, κ BV0 0 T ,000 PE 0 T ,000 CD IgG, κ APC 0 T ,000 CD B4 IgG, κ FITC 0 µg ,400 CD23 RIK-2 IgG PE 2 µg ,000 CD267 A- K2-M22 Rat IgG, κ APC 0 µg ,000
16 CD27 C40-47 IgG, κ AF647 2 T ,000 BV42 0 T ,000 BV0 0 T 634 4,000 PE 2 T ,000 0 T ,000 0 T ,000 0 T ,000 V40 0 T ,000 CD272 HMBT-6B2 Ham IgG PE 0 µg ,000 CD273 TY2 Rat IgG, κ BV42 0 µg ,000 CD274 MIH IgG, κ PE 2 T ,000 MIH Rat IgG, λ BV7 0 µg ,000 CD276 MIH32 Rat IgG, κ AF647 0 µg ,000 AF488 0 µg ,000 CD278 CD279 CD279 PD- DX29 IgG BV42 0 µg ,000 AF647 0 T ,000 BV42 0 T ,000 BV60 0 T ,000 BV7 0 T ,000 0 T ,000 7E.7G9 Rat IgG, κ AF647 0 µg ,000 BV42 0 µg ,000 MIH4 IgG, κ FITC 2 µg ,000 PE 2 T ,000 J43 Ar Ham IgG 2, κ EH2. IgG, κ APC 0 µg ,200 BV42 0 µg ,000 BV60 0 µg ,000 PE 2 µg ,900 0 µg ,200 BV42 0 T 626 4,000 BV0 0 T ,000 BV60 0 T ,000 BV60 0 T ,000 BV7 0 T ,000 BV786 0 T ,000 CD282 6C2 Rat IgG, κ AF647 0 µg ,00 CD294 CRTH2 BM6 Rat IgG, κ 0 T ,000 BV42 0 T ,000 CD294 BM6 Rat IgG, κ CD IgG CD34 NKG2D D IgG, κ CX Rat IgG, κ AF647 2 µg ,000 FITC 0 µg 669 3,000 0 µg ,000 V40 0 µg ,000 AF647 2 T ,000 PE 2 T ,000 APC 2 T ,000 BV0 0 T ,000 BV60 0 T ,000 BV7 0 T ,000 PE 2 µg 68 23,000 0 T ,000 0 T ,000 0 T ,000 APC 0 µg ,00 BV42 0 µg ,000 BV7 0 µg ,000 0 µg ,200 CD324 E-Cadherin 67A4 IgG, κ AF488 0 T ,000 AF647 0 T 637 4,000 0 T ,000 0 T ,000 Purified 0 µg ,000 CD32 8C IgG, κ 0 T ,000 AF647 0 T ,000 CD326 CD33 NKp46 EBA- IgG, λ BV0 0 T 638 4,000 BV42 0 T ,000 G8.8 Rat IgG, κ 9E2/Nkp46 IgG, κ 29A.4 Rat IgG, κ CD338 D3 IgG, κ BV60 0 T ,000 APC 0 µg ,000 BV42 0 µg ,000 BV0 0 µg ,000 BV7 0 µg ,000 PE 0 µg ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 BV7 0 T ,000 BV786 0 T ,000 0 T ,000 V40 0 T ,000 AF700 0 µg ,00 BV42 0 µg ,000 BV0 0 µg 634 4,000 BV60 0 µg ,000 V40 2 µg ,800 APC 0 T 64 33,000 BV42 0 T ,000 0 T ,000 CDX-2 M39-7 IgG, κ AF647 0 T ,000 PE 0 T ,000 Chondroitin Sulfate Clec9A Clec2A Cutaneous Lymphocyte Antigen IgG 3A4/Clec9A also known as 20/0-3A4 or 3A4 Rat IgG, κ AF488 0 T ,000 AF647 0 T ,000 PE 0 T ,000 PE 2 µg ,000 0B4 PE 0 µg ,200 0C IgG, κ FITC 0 T ,000 AF647 0 T ,000 PE 0 T ,000 D3 Rat IgG, κ PE 0 µg ,00 HECA-42 Rat IgM, κ FITC 2 T ,000 CXCR RF8B2 Rat IgG, κ BV42 0 T ,000 BV0 0 T 630 4,000 0 T ,000 Cyclin E HE2 IgG Purified 0 µg 9 40,000 Cytokeratin CAM.2 IgG, κ AF647 0 T ,000 BV0 0 T ,000 0 T ,000 Delta-Like Protein 30B. Rat IgG, κ PE 0 µg ,000 Delta-Like Protein 4 9A. Rat IgG, κ PE 0 µg ,000 6
17 Disialoganglioside GD2 DO-.0 Clonotypic TCR 4.G IgG, κ AF647 0 T ,000 BUV39 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 FITC 0 T ,000 PE 0 T ,000 0 T ,000 KJ-26 IgG, κ AF647 0 µg ,00 Doublecortin, 30/ Doublecortin IgG PE 0 T 60 43,000 Early B Lineage E-Cadherin AA4. Rat IgG, κ FITC 0 µg ,000,, Rat, 36/ Dog E-Cadherin IgG, κ PE 0 T ,000 EGF Receptor EGFR. IgG, κ AF647 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 0 T ,000 ERK/2 pt202/py204,, Rat 20A IgG BV42 0 T ,000 Erythroid Cells EZH2 F4/80-Like Receptor Rat HIS49 IgM, κ APC 0 µg ,000,, Rat, Dog, Chick /EZH2 IgG AF488 0 T ,000 AF647 0 T ,000 BV42 0 T ,000 PE 0 T ,000 6F2 Rat IgG, κ BV0 0 µg ,000 BV42 0 µg ,000 PE 0 µg ,000 Fcµ Receptor HM4- IgG, κ Biotin 0 µg ,000 PE 0 T ,000 Fibronectin Flk- HM7-0 IgG, κ PE 0 T ,000 0/ IgG AF488 0 T ,000 Fibronectin IgG AF647 0 T ,000 Avas lpha Rat IgG, κ APC 2 µg ,000 0 µg 622 3,200 BV42 0 µg ,000 PE 2 µg 602 9,000 0 µg 629 3,200 0 µg ,000 V40 0 µg ,200 FoxA2 N7-280 IgG, κ PE 0 T ,000 Foxp3 29D/C7 IgG MF23 Rat IgG AF488 2 T ,000 AF647 2 T ,000 PE 2 T ,000 0 T ,000 V40 30 T ,000 AF488 2 µg ,800 AF647 2 µg ,800 BV42 0 µg ,000 PE 2 µg ,800 0 µg ,200 V40 0 µg ,200 R6-7 Rat IgG, κ AF647 0 µg ,000 AF488 0 µg ,000 GARP 7B IgG, κ GATA3, L0-823 IgG, κ 0 T ,000 AF488 0 T ,000 AF647 0 T ,000 BV42 0 T ,000 PE 0 T ,000 0 T ,000 0 T ,000 GATA4 L97-6 IgG, κ AF647 0 T ,000 AF488 0 T ,000 GFAP GM-CSF,, Rat, Pig, Dog, Chick, Rab, B4 Bov, G Pig, Sheep BVD2-2C IgG Rat IgG Granzyme B GB IgG, κ PE 0 T ,000 AF488 0 T ,000 AF647 0 T ,000 PE 0 T ,000 AF647 0 T ,000 BV42 0 T ,000 0 T ,000 0 T ,000 AF647 2 µg ,000 AF700 2 µg ,000 BV42 0 T ,000 BV0 0 T ,000 FITC 2 T ,000 V40 0 T 6 4,000 H2AX ps39, N-43 IgG, κ PE 0 T ,000 H-2D b KH9 IgG, κ FITC 0 µg ,000 H-2D d IgG, κ FITC 0 µg ,00 H-2K b AF6-88. IgG, κ AF647 0 µg ,00 BV42 0 µg ,000 FITC 0 µg ,000 PE 2 µg ,400 0 µg ,000 H-2K d SF-. IgG, κ FITC 0 µg ,000 PE 2 µg ,400 H-2K k IgG, κ FITC 0 µg ,000 Helios, 22F6 Ar Ham IgG PE 0 µg ,000 Histone H3 ps28 HTA28 Rat IgG, κ V40 0 T ,000 HLA-A2 BB7.2 IgG, κ HLA-A, B, C, Rhe, G IgG, κ AF700 0 T ,000 APC 0 T ,000 H7 0 T ,000 FITC 2 µg ,000 0 T ,000 0 T ,000 V40 0 T ,000 APC 2 T ,000 FITC 2 T ,000 FITC 0 T ,000 PE 2 T ,000 PE 0 T ,000 0 T ,000 V40 0 T ,000 7
18 HLA-DR HLA-DR, DP, DQ I-A/I-E G46-6 IgG, κ AF700 0 T ,000, Rhe, APC 0 T ,000, Rhe,, Dog APC 2 T ,000 H7 0 T ,000 BUV39 0 T ,000 BV42 2 T ,000 BV0 0 T ,000, Rhe, BV60 2 T ,000 BV7 0 T ,000, Rhe,, Dog, Rhe,, Dog, Rhe,, Dog FITC 2 T ,000 FITC 0 T ,000 PE 2 T ,000 PE 0 T ,000 Cy 2 T ,000 2 T ,000 0 T ,000 0 T ,000 0 T ,000 V40 0 T ,000 V00 2 T ,000 AF647 0 T ,000 Tu39 IgG, κ FITC 2 T ,000, Rhe, FITC 0 T ,000 2G9 Rat IgG, κ M/4..2 I-Ab AF6-20. IgG, κ FITC 0 µg ,400 AF488 0 µg ,00 AF647 0 µg ,00 BV42 0 µg ,000 BV60 0 µg ,000 BV60 0 µg 634 4,000 BV7 0 µg ,000 PE 2 µg ,000 0 µg ,000 V00 0 µg ,00 APC 0 µg ,000 BV42 0 µg ,000 FITC 0 µg 620 6,000 PE 2 µg ,400 0 µg ,200 I-Ad MS AMS-32. IgG, κ FITC 0 µg ,400 I-Ak IgG, κ FITC 0 µg ,000 I-Ek 4-4-4S IgG, κ FITC 0 µg ,400 IFN- α 7N4- IgG, κ V40 0 T ,000 IFN- γ 4S.B3 B27 IgG, κ BV60 0 T ,000 BV786 0 T ,000 FITC 2 µg ,000 PE 2 µg 606 2,000 2 µg ,000 AF700 2 µg ,000 APC 2 µg ,000 BUV39 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 BV7 0 T ,000 FITC 2 µg ,000 IFN- γ Ig, κ Light Chain, Rhe,, Rhe, B27 4S.B3 IgG, κ XMG.2 Rat IgG, κ Pig P2G0 IgG, κ FITC 0 T ,000 PE 2 T ,000 0 T ,000 2 T ,000 0 T ,000 V40 30 T ,000 V00 0 T ,000 AF647 0 T ,000 APC 0 T 38 44,000 FITC 0 T ,000 PE 0 T ,000 0 T ,000 0 T ,000 APC 2 µg ,000 0 µg ,200 BV42 0 µg ,000 BV60 0 µg ,000 BV786 0 µg ,000 FITC 2 µg ,000 PE 2 µg ,000 2 µg ,600 2 µg ,000 0 µg ,000 V40 0 µg ,200 AF647 0 µg ,000 0 µg ,000 Rat DB- AF647 0 T ,000 G20-93 IgG, κ 87. Rat IgG, κ AF700 0 T 639 4,000 APC 0 T ,000 H7 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T 628 4,000 FITC 2 T ,000 PE 2 T ,000 0 T ,000 0 T ,000 0 T ,000 V40 0 T ,000 AF700 0 µg 63 37,00 0 µg 633 3,200 BV42 0 µg ,000 PE 2 µg ,900 0 µg ,200 0 µg ,000 0 µg ,000 V40 0 µg ,400 8
19 IgD IA6-2 IgG, κ -26c. Rat IgG, κ IgE R3-72 Rat IgG, κ IgG A8- Rat IgG, κ AF700 0 T ,000 APC 0 T ,000 H7 0 T ,000 BUV39 0 T ,000 BV42 0 T 628 4,000 BV0 0 T ,000 BV60 0 T ,000 FITC 2 T ,000 PE 2 T ,000 0 T ,000 0 T ,000 0 T 63 40,000 V40 0 T ,000 V00 0 T ,000 APC 0 µg ,300 BV0 0 µg 630 4,000 BV60 0 µg ,000 BV786 0 µg ,000 FITC 0 µg ,400 V40 0 µg ,200 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 BV786 0 µg ,000 BV42 0 µg ,000 BV60 0 µg ,000 FITC 2 µg ,000 PE 2 µg ,900 0 µg 629 3,200 V40 0 µg ,200 IgG R9- Rat IgG, κ BV60 0 µg ,000 IgG G8-4 IgG, κ IgM G20-27 IgG, κ II/4 R Rat IgG, κ FITC 0 µg ,400 AF700 0 T ,000 APC 2 T ,000 H7 0 T ,000 BUV39 0 T ,000 BV42 0 T 628 4,000 BV0 0 T ,000 BV60 0 T ,000 FITC 2 T ,000 PE 2 T 609 2,000 0 T ,000 0 T ,000 V40 0 T ,000 APC 2 T ,000 BUV39 0 T ,000 BV42 0 T ,000 BV0 0 T 633 4,000 BV60 0 T ,000 FITC 2 T ,000 PE 2 T ,000 Cy 0 T ,000 2 T ,000 0 T ,000 V40 0 T ,000 APC 2 µg ,900 BUV39 0 µg ,000 BV42 0 µg 629 4,000 BV0 0 µg 638 4,000 IgM R Rat IgG, κ IKK γ ps376 N9-39 IL-2 IL IgG, κ BV60 0 µg ,000 BV7 0 µg ,000 BV786 0 µg ,000 PE 2 µg ,000 0 µg 626 3,200 2 µg ,600 V40 0 µg ,200 Purified 0 µg ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 BV60 0 T ,000 BV7 0 T ,000 0 T ,000 V40 0 T ,000 APC 2 µg ,000, Rhe, APC 0 T 383 2,000 FITC 0 T 936 3,000 FITC 2 µg 60 23,000 JES6-H4 Rat IgG, Rhe, Cyno, Rhe, Cyno 8D4-8 IgG, κ B Rat IgG, Rhe, MQ- 7H2 Rat IgG, κ PE 0 T ,000 PE 2 T ,000 0 T ,000 0 T ,000 AF700 0 µg ,00 APC 2 µg ,000 0 µg ,000 BV42 0 µg ,000 BV60 0 µg 639 4,000 FITC 2 µg ,000 PE 2 µg 606,000 0 µg ,200 0 µg ,00 0 µg ,000 V40 0 µg ,200 APC 0 T ,000 BV42 0 T ,000 PE 2 T ,000 PE 0 T ,000 0 T ,000 0 T ,000 V40 0 T 69 40,000 APC 2 µg ,000 BV42 0 µg 629 4,000 BV60 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 BV786 0 µg ,000 PE 2 µg ,000 0 µg ,200 0 µg ,900 0 µg ,900 V40 0 µg ,200 MP4-2D2 FITC 2 µg ,000 9
20 IL-, TRFK Rat IgG IL-6 MQ2-3A Rat IgG, Rhe, Cyno APC 2 µg ,000 PE 2 µg ,000 APC 0 T ,000 BV42 0 T ,000 0 T ,000 V40 0 T ,000 MQ2-6A3 Rat IgG, κ PE 0 T 473 2,300 MP-20F3 Rat IgG IL-8 G26-8 IgG IL-9 IL-0 IL-2 p40/p70 MH9A3 IgG, κ AF488 0 µg ,00 APC 0 µg ,00 PE 2 µg ,000 V40 0 µg ,200 BV42 0 T ,000 BV0 0 T 633 4,000 0 T ,000 AF647 2 T 608 2,000 PE 2 T ,000 D9302C2 Ar Ham IgG 2, κ JES3-9F Rat IgG, Vir JES3-9D7 Rat IgG JES-6E3 Rat IgG 0 T ,000 0 µg ,200 APC 2 µg ,000 PE 2 T ,000 0 T ,000 BV42 0 T ,000 BV60 0 T ,000 BV60 0 T 640 4,000 BV7 0 T ,000 BV786 0 T ,000 APC 2 µg 609 7,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 FITC 2 µg ,000 PE 2 µg ,000 V40 0 µg ,200 Rat A-4 IgG AF647 0 µg ,000 C. IgG V40 0 T ,000 C.6 Rat IgG IL-3 JES0-A2 Rat IgG IL-7A N49-63 SCPL362 IgG, κ PE 2 µg ,800 V40 0 µg ,200 APC 0 T ,000 BV42 0 T ,000 PE 2 µg ,000 V40 0 T 68 4,000 AF488 2 T ,000 AF647 2 T ,000 AF700 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 BV786 0 T ,000 PE 2 T ,000 V40 0 T ,000 AF647 2 T ,000 PE 2 T ,000 IL-7A IL-7F TC- 8H0 O O Rat IgG, κ IgG, κ IL-2 3A3-N2. IgG IL-23 Receptor IL-27 p28 IL-30 AF488 2 µg ,000 AF647 2 µg ,000 AF700 0 µg ,00 0 µg ,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 BV60 0 µg ,000 PE 2 µg ,000 0 µg ,200 V40 0 µg ,200 AF488 2 T ,000 AF647 2 T ,000 PE 2 T 698 2,000 2 T ,000 V40 2 T ,000 AF488 2 µg 668 2,900 AF647 2 µg 667 2,900 PE 2 µg 666 9,000 0 µg ,200 0 µg ,900 AF647 2 T ,000 PE 2 T ,000 3C9 IgG, κ PE 2 µg ,900 O Rat IgG, κ PE 0 µg ,200 MM27.7B IgG, κ APC 0 µg ,200 ILT7 CD8g 7G0.2 IgG, κ 0 T ,000 BV42 0 T ,000 Invariant NK T-Cell 6B IgG, κ BV0 0 T ,000 PE 2 T 620 2,000 BV7 0 T ,000 Islet-, Q-46 IgG, κ PE 0 T ,000 Ki-67 3/Ki-67 IgG FITC 0 µg ,000 AF488 0 T 66 40,000 AF647 0 T ,000 AF700 0 T ,000 IgG, κ BUV39 0 T ,000 IgG BV42 0 T ,000 BV0 0 T ,000 B6 IgG, BV60 0 T ,000 κ,, Pig BV7 0 T 637 4,000 IgG BV786 0 T ,000 0 T ,000 0 T ,000 V40 0 T ,000 AF488 0 µg ,00 APC 0 µg ,200 BV42 0 µg ,000 BV60 0 µg ,000 KLRG 2F Syr Ham IgG, κ 2 BV7 0 µg ,000 LAP TW4-2F8 IgG, κ PE 0 µg ,400 0 µg ,000 V40 0 µg ,00 0 T ,000 0 T ,000 TW7-6B4 PE 0 µg ,000 20
21 Lgr Central LRR Central LRR Lgr N-Terminal 8F2 Rat IgG, κ Light Chain, λ JDC-2 IgG, κ 4DF8 Rat IgG, λ Biotin 0 µg ,000 AF647 0 T ,000 AF647 0 T ,000 Biotin 0 µg ,000 BV42 0 T ,000 BV0 0 T 632 4,000 0 T ,000 AF647 0 T ,000 BV42 0 T ,000 BV0 0 T ,000 BV60 0 T ,000 FITC 2 T ,000 PE 2 T ,000 V40 0 T ,000 Lin-28 6DF9 IgG, κ AF488 0 T ,000 PE 0 T ,000 LPAM- DATK32 Rat IgG, κ Ly-6A/E D7 E3-6.7 Rat IgG, κ Ly-6C AL-2 Rat IgM, κ APC 0 µg ,000 BV42 0 µg ,000 0 µg ,200 BV786 0 µg ,000 BUV39 0 µg 0 µg , ,000 BV42 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 FITC 2 µg ,000 PE 2 µg ,400 0 µg ,200 2 µg 602 7,000 V40 0 µg ,200 V00 2 µg ,00 FITC 2 µg ,300 PE 2 µg ,400 AF700 0 µg ,00 APC 0 µg ,00 0 µg ,000 BV42 0 µg ,000 BV60 0 µg 630 4,000 FITC 2 µg 608 7,00 0 µg ,200 0 µg ,000 0 µg ,000 V40 0 µg ,200 Ly-6D 49-H4 Rat IgG c, κ AF647 0 µg ,00 2 Ly-6G A8 Rat IgG, κ AF700 0 µg ,00 APC 0 µg ,000 BUV39 0 µg 0 µg , ,000 BV42 0 µg ,000 BV60 0 µg ,000 BV7 0 µg ,000 FITC 2 µg 60 0,000 PE 2 µg 604 4,700 0 µg ,200 0 µg ,000 Ly-6G A8 Rat IgG, κ Ly-6G/Ly-6C RB6-8C Rat IgG, κ 0 µg ,00 V40 0 µg ,200 APC 2 µg 6083,000 BUV39 0 µg ,000 BV42 0 µg ,000 BV0 0 µg ,000 BV60 0 µg ,000 FITC 2 µg 62060,300 PE 2 µg ,700 0 µg , µg 298 3,000 2 µg 603 9,000 V40 2 µg ,800 Ly-49AB6 A IgG, κ V40 0 µg ,200 Ly-49D 4E Rat IgG, κ FITC 0 µg ,000 Ly-49G2 4D Rat IgG, κ 0 µg ,000 Ly-49H 3D0 IgG, κ 0 µg 629 3,200 FITC 0 µg ,000 Ly- 6C3 Rat IgG, κ FITC 0 µg ,000 Mac-3 M3/84 Rat IgG, κ FITC 0 µg ,400 MAP2B MCP- 8/MAP2B IgG, AF647 0 T ,000 κ, Rat AF488 0 T ,000, Rhe, Cyno D3-F7 IgG, κ PE 0 T ,300 AF647 0 T ,000 MEK ps28 / MEK2 ps222, O IgG, κ PE 0 T ,000 MIP- α, Rhe, Cyno MIP- β D2-3 IgG Monocyte/ Granulocyte A3 IgG, κ APC 0 T 33 37,000 AF700 0 T ,000 APC 0 T ,000 H7 0 T ,000 BV42 0 T ,000 PE 2 µg 620 2,000 0 T ,000 0 T ,000 V40 0 T ,000 Pig A IgG, κ FITC 0 µg ,000 PE 0 µg ,000 MSI N4-47 IgG, κ PE 0 T ,000 Myogenin Nanog,, Rat, FD Cat IgG PE 0 T ,000 N3-3 M-32 IgG, κ AF488 0 T ,000 AF647 0 T ,000 PE 2 T ,000 AF488 0 T ,600 AF647 0 T ,600 PE 0 T ,600 NCAM- R9-760 IgG, κ PE 0 T ,000 Nestin, Rat 2/NESTIN IgG, κ AF647 0 T ,000 PE 0 T ,000 0 T ,000 V40 0 T 6 4,000 NeuroD, R8-294 IgG, κ PE 0 T ,000 AF647 0 T ,000 2
Welcome to a ore Colorful World BD BD Horizon Brilliant Violet x 1, Lymph x 1, CD3+ CD8 PerCP-Cy5-5-A CD4+ 5 1
Brilliant Violet マルチカラー トレーニング キャンペーン BD Brilliant Violet 2 ( ) 1 ( ) P12 Brilliant Violet Welcome to a ore Colorful World BD BD Horizon Brilliant Violet x 1, 5 1 15 2 25 Lymph x 1, 5 1 15 2 25 CD3+ CD8
BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mouse IgG , ,000 BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mous
Bio X Cell 社価格表 (2018 年 4 月 ) < 株式会社シン コーポレーション > Bio X Cell 社価格表 (2018 年 4 月 ) ご注文ごとに別途取扱手数料 (2( 万円 税別 ) を申し受けます 大学向け価格でのご購入には アカデミックプライス適用申込書のご提出が必須となります 品番クローン品名イソタイプ 容量 (mg) 大学向希望小売価格 ( 円 ) 税別 希望小売価格
2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1
Mg-LPSO 2566 2016 3 2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1 1,.,,., 1 C 8, 2 A 9.., Zn,Y,.
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載
1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( 電圧や系統安定度など ) で連系制約が発生する場合があります
( )
18 10 01 ( ) 1 2018 4 1.1 2018............................... 4 1.2 2018......................... 5 2 2017 7 2.1 2017............................... 7 2.2 2017......................... 8 3 2016 9 3.1 2016...............................
170920_BioXCell社カタログ改訂2【9校】.indd
BULK ANTIBODIES for in vivo RESEARCH Bio X Cell in vivo InVivoPlus 0.001 EU/ug 95 5 FACS ELISA 4-1BB CD137 Mouse LOB12.3 Rat IgG1 4-1BB activation BP0169 CD3 ε Mouse 145-2C11 Armenian Hamster IgG1 DP,
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 7 月 31 日 CPC 版が発効します 原文及び詳細はCPCホームページのCPC Revision
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 7 月 31 日 CPC 2019.08 版が発効します 原文及び詳細はCPCホームページのCPC Revisions(CPCの改訂 ) をご覧ください https://www.cooperativepatentclassification.org/cpcrevisions/noticeofchanges.html
空き容量一覧表（154kV以上）
1/3 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量 覧 < 留意事項 > (1) 空容量は 安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発 する場合があります (3) 表 は 既に空容量がないため
2/8 一次二次当該 42 AX 変圧器 なし 43 AY 変圧器 なし 44 BA 変圧器 なし 45 BB 変圧器 なし 46 BC 変圧器 なし
1/8 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載のない限り 熱容量を考慮した空き容量を記載しております その他の要因 ( や系統安定度など ) で連系制約が発生する場合があります (3)
000 001
all-round catalogue vol.2 000 001 002 003 AA0102 AA0201 AA0701 AA0801 artistic brushes AA0602 AB2701 AB2702 AB2703 AB2704 AA0301 AH3001 AH3011 AH3101 AH3201 AH3111 AB3201 AB3202 AB2601 AB2602 AB0701 artistic
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 1 月 17 日 CPC 版のプレ リリースが公開されました 原文及び詳細はCPCホームページの C
欧州特許庁米国特許商標庁との共通特許分類 CPC (Cooperative Patent Classification) 日本パテントデータサービス ( 株 ) 国際部 2019 年 1 月 17 日 CPC 2019.02 版のプレ リリースが公開されました 原文及び詳細はCPCホームページの CPC Revisions(CPCの改訂 ) 内のPre-releaseをご覧ください http://www.cooperativepatentclassification.org/cpcrevisions/prereleases.html
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
21 1 1 1 2 2 5 7 9 11 13 13 14 18 18 20 28 28 29 31 31 34 35 35 36 37 37 38 39 40 56 66 74 89 99 - ------ ------ -------------- ---------------- 1 10 2-2 8 5 26 ( ) 15 3 4 19 62 2,000 26 26 5 3 30 1 13
MACSスターティングキットの選択方法
ミルテニーバイオテク株式会社 初めての MACS スターティングキットの選択方法 初めて MACS テクノロジーによる細胞分離をお試しになる場合は スターティングキットが最適です スターティングキットは 細胞分離に 必要な機器と試薬がセットなっており 個々にご購入いただくよりも安価でご利 いただけます 多様な実験系のために 13 種類のスター ティングキットをご 意しています 選択方法に従って 最適なキットをお選びください
PLC HMI High flexibility Simple networking Easy to use 190 HMI 2
PLC HMI High flexibility Simple networking Easy to use 190 HMI 2 Contents 4 11 14 15 3 SIMATIC PLC190 24 S7-1200/ S7-1200 S7-1200 I/OCPU ROM SIMATIC S7-1200PLC 4 S7-1200 CPU 100Mbps HMI-PLCPC-PLCPLC16
1. 2 P 2 (x, y) 2 x y (0, 0) R 2 = {(x, y) x, y R} x, y R P = (x, y) O = (0, 0) OP ( ) OP x x, y y ( ) x v = y ( ) x 2 1 v = P = (x, y) y ( x y ) 2 (x
. P (, (0, 0 R {(,, R}, R P (, O (0, 0 OP OP, v v P (, ( (, (, { R, R} v (, (, (,, z 3 w z R 3,, z R z n R n.,..., n R n n w, t w ( z z Ke Words:. A P 3 0 B P 0 a. A P b B P 3. A π/90 B a + b c π/ 3. +
() () () () () 175 () Tel Fax
JPCA-PE04-02-01-02-01S JPCA PE04-02-01-02-01S 2005 () () () () () 175 () 167-0042 3122 2 Tel 03-5310-2020Fax 03-5310-2021e-mailstd@jpca.org Detail Specification for PT Optical Module 1 PT PT 12 Optoelectronic
2012 A, N, Z, Q, R, C
2012 A, N, Z, Q, R, C 1 2009 9 2 2011 2 3 2012 9 1 2 2 5 3 11 4 16 5 22 6 25 7 29 8 32 1 1 1.1 3 1 1 1 1 1 1? 3 3 3 3 3 3 3 1 1, 1 1 + 1 1 1+1 2 2 1 2+1 3 2 N 1.2 N (i) 2 a b a 1 b a < b a b b a a b (ii)
_19MY_E-PACE
JAGUAR E- PACE PECIFICATION AND PRICE GUIDE ELECT PACK セレクトパック セレクトパック セレクトパック 066AC 129AA 070AV 070BA 017TB 119,000 80,000 087AU 011CB 064GK 300CF 064Q HE セレクトパック セレクトパック 119,000 119,000 119,000 99,000
CRA3689A
AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF
linearal1.dvi
19 4 30 I 1 1 11 1 12 2 13 3 131 3 132 4 133 5 134 6 14 7 2 9 21 9 211 9 212 10 213 13 214 14 22 15 221 15 222 16 223 17 224 20 3 21 31 21 32 21 33 22 34 23 341 23 342 24 343 27 344 29 35 31 351 31 352
untitled
0. =. =. (999). 3(983). (980). (985). (966). 3. := :=. A A. A A. := := 4 5 A B A B A B. A = B A B A B B A. A B A B, A B, B. AP { A, P } = { : A, P } = { A P }. A = {0, }, A, {0, }, {0}, {}, A {0}, {}.
<8DD AA97A3834C B BF8A69838A C8EA E786C7378>
ST-01738 ErythroClear Red Blood Cell Depletion Reagent kit 臍帯血 2 ml 用 17,000 13,600 ST-01739 ErythroClear Red Blood Cell Depletion kit 臍帯血 2 ml 用 475,000 380,000 ST-07801 Lymphoprep 250 ml 17,000 13,600
x, y x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 xy (x y) (x + y) xy (x y) (x y) ( x 2 + xy + y 2) = 15 (x y)
x, y x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 1 1977 x 3 y xy 3 x 2 y + xy 2 x 3 + y 3 = 15 xy (x y) (x + y) xy (x y) (x y) ( x 2 + xy + y 2) = 15 (x y) ( x 2 y + xy 2 x 2 2xy y 2) = 15 (x y) (x + y) (xy
IMO 1 n, 21n n (x + 2x 1) + (x 2x 1) = A, x, (a) A = 2, (b) A = 1, (c) A = 2?, 3 a, b, c cos x a cos 2 x + b cos x + c = 0 cos 2x a
1 40 (1959 1999 ) (IMO) 41 (2000 ) WEB 1 1959 1 IMO 1 n, 21n + 4 13n + 3 2 (x + 2x 1) + (x 2x 1) = A, x, (a) A = 2, (b) A = 1, (c) A = 2?, 3 a, b, c cos x a cos 2 x + b cos x + c = 0 cos 2x a = 4, b =
SB-80DX SB-80DX (Jp) Jp
SB-80DX SB-80DX (Jp) Jp 2 3 4 5 6 7 k k k k k k k k k k k k k k k k 8 k k 9 k 10 k k k k k k k 11 12 13 1 5 6 2 7 8 3 4 9 10 11 12 13 14 14 1 k 8 k 2 k 9 k 3 k 10 k 4 k 5 k 11 k 6 k 12 7 k 13 14 15 16
O E ( ) A a A A(a) O ( ) (1) O O () 467
1 1.0 16 1 ( 1 1 ) 1 466 1.1 1.1.1 4 O E ( ) A a A A(a) O ( ) (1) O O () 467 ( ) A(a) O A 0 a x ( ) A(3), B( ), C 1, D( 5) DB C A x 5 4 3 1 0 1 3 4 5 16 A(1), B( 3) A(a) B(b) d ( ) A(a) B(b) d AB d = d(a,
x V x x V x, x V x = x + = x +(x+x )=(x +x)+x = +x = x x = x x = x =x =(+)x =x +x = x +x x = x ( )x = x =x =(+( ))x =x +( )x = x +( )x ( )x = x x x R
V (I) () (4) (II) () (4) V K vector space V vector K scalor K C K R (I) x, y V x + y V () (x + y)+z = x +(y + z) (2) x + y = y + x (3) V x V x + = x (4) x V x + x = x V x x (II) x V, α K αx V () (α + β)x
学習の手順
NAVI 2 MAP 3 ABCD EFGH D F ABCD EFGH CD EH A ABC A BC AD ABC DBA BC//DE x 4 a //b // c x BC//DE EC AD//EF//BC x y AD DB AE EC DE//BC 5 D E AB AC BC 12cm DE 10 AP=PB=BR AQ=CQ BS CS 11 ABCD 1 C AB M BD P
iii 1 1 1 1................................ 1 2.......................... 3 3.............................. 5 4................................ 7 5................................ 9 6............................
A B 5 C 9 3.4 7 mm, 89 mm 7/89 = 3.4. π 3 6 π 6 6 = 6 π > 6, π > 3 : π > 3
π 9 3 7 4. π 3................................................. 3.3........................ 3.4 π.................... 4.5..................... 4 7...................... 7..................... 9 3 3. p
1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e
No. 1 1 1 H Li Be Na M g B A l C S i N P O S F He N Cl A e K Ca S c T i V C Mn Fe Co Ni Cu Zn Ga Ge As Se B K Rb S Y Z Nb Mo Tc Ru Rh Pd Ag Cd In Sn Sb T e I X e Cs Ba F Ra Hf Ta W Re Os I Rf Db Sg Bh
X G P G (X) G BG [X, BG] S 2 2 2 S 2 2 S 2 = { (x 1, x 2, x 3 ) R 3 x 2 1 + x 2 2 + x 2 3 = 1 } R 3 S 2 S 2 v x S 2 x x v(x) T x S 2 T x S 2 S 2 x T x S 2 = { ξ R 3 x ξ } R 3 T x S 2 S 2 x x T x S 2
36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
取扱説明書 -詳細版- 液晶プロジェクター CP-AW3019WNJ
B A C D E F K I M L J H G N O Q P Y CB/PB CR/PR COMPONENT VIDEO OUT RS-232C LAN RS-232C LAN LAN BE EF 03 06 00 2A D3 01 00 00 60 00 00 BE EF 03 06 00 BA D2 01 00 00 60 01 00 BE EF 03 06 00 19 D3 02 00
A G A G A G 4 1 1 2 3 4 5 6 7 110119118 b A G C G 4 1 7 * * G A C b a HIKJ K J L f B c g 9 K c d g e 7 G 7 1 G 1 aa g g g c L M G L H G G 4 aa c c A a c CB B C A G f A G f G 9 8 1 2
熊本県数学問題正解
00 y O x Typed by L A TEX ε ( ) (00 ) 5 4 4 ( ) http://www.ocn.ne.jp/ oboetene/plan/. ( ) (009 ) ( ).. http://www.ocn.ne.jp/ oboetene/plan/eng.html 8 i i..................................... ( )0... (
1990 IMO 1990/1/15 1:00-4:00 1 N N N 1, N 1 N 2, N 2 N 3 N 3 2 x x + 52 = 3 x x , A, B, C 3,, A B, C 2,,,, 7, A, B, C
0 9 (1990 1999 ) 10 (2000 ) 1900 1994 1995 1999 2 SAT ACT 1 1990 IMO 1990/1/15 1:00-4:00 1 N 1990 9 N N 1, N 1 N 2, N 2 N 3 N 3 2 x 2 + 25x + 52 = 3 x 2 + 25x + 80 3 2, 3 0 4 A, B, C 3,, A B, C 2,,,, 7,
untitled
( ) c a sin b c b c a cos a c b c a tan b a b cos sin a c b c a ccos b csin (4) Ma k Mg a (Gal) g(98gal) (Gal) a max (K-E) kh Zck.85.6. 4 Ma g a k a g k D τ f c + σ tanφ σ 3 3 /A τ f3 S S τ A σ /A σ /A
1. z dr er r sinθ dϕ eϕ r dθ eθ dr θ dr dθ r x 0 ϕ r sinθ dϕ r sinθ dϕ y dr dr er r dθ eθ r sinθ dϕ eϕ 2. (r, θ, φ) 2 dr 1 h r dr 1 e r h θ dθ 1 e θ h
IB IIA 1 1 r, θ, φ 1 (r, θ, φ)., r, θ, φ 0 r
RIDGID_Catalog_2016_web.pdf
K-1/K-3/K-6 115 K-5 116 116 117 K-26 117 K-25 117 K-30 118 K-45AF 119 120 K-40AF 121 K-400 123 K-3800 125 K-6200 127 K-50 129 K-1500 131 KJ-2200 133 135 114 46683 K-1 K-1 K-1 46683 K-1 59787 K-3 59797
( )
7..-8..8.......................................................................... 4.................................... 3...................................... 3..3.................................. 4.3....................................
Amnis TM CellStream TM CellStream TM
Amnis TM CellStream TM CellStream TM Amnis TM CellStream TM Amnis TM CCD FITC PE 5 96 7 CFR Part FDA TM CellStream Luminex Time Delay Integration TDI CellStream. 7... CCD CellStream Amnis CCD CellStream
Product News (IAB)
プロダクトニュース生産終了予定商品のお知らせ発行日 2016 年 3 月 1 日 押ボタンスイッチ / 表示灯 No. 2016025C 押ボタンスイッチ形 A22 シリーズ一部商品 ツマミ形セレクタスイッチ形 A22S シリーズ一部商品 形 A22W シリーズ一部商品 キー形セレクタスイッチ形 A22K シリーズ一部商品 表示灯形 M22 シリーズ一部商品生産終了のお知らせ 生産終了予定商品 押ボタンスイッチ
D 24 D D D
5 Paper I.R. 2001 5 Paper HP Paper 5 3 5.1................................................... 3 5.2.................................................... 4 5.3.......................................... 6
Gauss Gauss ɛ 0 E ds = Q (1) xy σ (x, y, z) (2) a ρ(x, y, z) = x 2 + y 2 (r, θ, φ) (1) xy A Gauss ɛ 0 E ds = ɛ 0 EA Q = ρa ɛ 0 EA = ρea E = (ρ/ɛ 0 )e
7 -a 7 -a February 4, 2007 1. 2. 3. 4. 1. 2. 3. 1 Gauss Gauss ɛ 0 E ds = Q (1) xy σ (x, y, z) (2) a ρ(x, y, z) = x 2 + y 2 (r, θ, φ) (1) xy A Gauss ɛ 0 E ds = ɛ 0 EA Q = ρa ɛ 0 EA = ρea E = (ρ/ɛ 0 )e z
05秋案内.indd
1 2 3 4 5 6 7 R01a U01a Q01a L01a M01b - M03b Y01a R02a U02a Q02a L02a M04b - M06b Y02a R03a U03a Q03a L03a M08a Y03a R04a U04a Q04a L04a M09a Y04a A01a L05b, L07b, R05a U05a Q05a M10a Y05b - Y07b L08b
高校生の就職への数学II
II O Tped b L A TEX ε . II. 3. 4. 5. http://www.ocn.ne.jp/ oboetene/plan/ 7 9 i .......................................................................................... 3..3...............................
FCシリンダ
CAT. No. KS-570-01 C ujikura cylinder INDEX Page CS - - -22 CS - -3 - CD - -3 - CS -40-0 -4 CD -40-0 -4 CS - -20-3 CD - -20-3 CL-400 VCS CDR -400 1 ujikura Cylinders 2 3 4 C 0 3 0.0.7 00 CD 0 4 S0 P CS
2011de.dvi
211 ( 4 2 1. 3 1.1............................... 3 1.2 1- -......................... 13 1.3 2-1 -................... 19 1.4 3- -......................... 29 2. 37 2.1................................ 37
PII S (96)
C C R ( 1 Rvw C d m d M.F. Pllps *, P.S. Hp I q G U W C M H P C C f R 5 J 1 6 J 1 A C d w m d u w b b m C d m d T b s b s w b d m d s b s C g u T p d l v w b s d m b b v b b d s d A f b s s s T f p s s
20 6 4 1 4 1.1 1.................................... 4 1.1.1.................................... 4 1.1.2 1................................ 5 1.2................................... 7 1.2.1....................................
Z 2 10Z MPa MPa MPa MPa 1.5MPa s s s JIS 6g/6H SD SD/B LB LS
3 03 0.01MPa 0.1MPa 0.1MPa 0.01MPa 1.MPa 0s 0s 0s JIS g/h SDSD/BLB LS0 F FBTT/BTB TB/BCUCU/B SDLCFTT/B TCTC/BDBD SDSD/BLB LS0 F FBTT/BTB TB/BCUCU/B SDLBFTT/B SKSPLK LP FKFP SKSPLK LP FKFP TKTPDPBDBP TKTPDPBDBP
<93FA97A AC C837288EA97972E786C7378>
日立ブラウン管テレビ一覧 F-500 SF-100 FMB-300 FMB-490 FMB-790 FMB-290 SMB-300 FMB-310G FMB-780 FMY-480 FMY-110 TOMY-100 FMY-520 FMY-320G SMY-110 FMY-510 SMY-490 FMY-770 FY-470 TSY-120 FY-340G FY-280 FY-450 SY-330
1 1 n 0, 1, 2,, n n 2 a, b a n b n a, b n a b (mod n) 1 1. n = (mod 10) 2. n = (mod 9) n II Z n := {0, 1, 2,, n 1} 1.
1 1 n 0, 1, 2,, n 1 1.1 n 2 a, b a n b n a, b n a b (mod n) 1 1. n = 10 1567 237 (mod 10) 2. n = 9 1567 1826578 (mod 9) n II Z n := {0, 1, 2,, n 1} 1.2 a b a = bq + r (0 r < b) q, r q a b r 2 1. a = 456,
PowerPoint プレゼンテーション
Isotype 略語紹介 AF 488 Alexa Fluor 488 AF 594 Alexa Fluor 594 AF 647 Alexa Fluor 647 AF 700 Alexa Fluor 700 BV 421 Brilliant Violet 421 BV 510 Brilliant Violet 510 BV 570 Brilliant Violet 570 BV 605 Brilliant
(4) P θ P 3 P O O = θ OP = a n P n OP n = a n {a n } a = θ, a n = a n (n ) {a n } θ a n = ( ) n θ P n O = a a + a 3 + ( ) n a n a a + a 3 + ( ) n a n
3 () 3,,C = a, C = a, C = b, C = θ(0 < θ < π) cos θ = a + (a) b (a) = 5a b 4a b = 5a 4a cos θ b = a 5 4 cos θ a ( b > 0) C C l = a + a + a 5 4 cos θ = a(3 + 5 4 cos θ) C a l = 3 + 5 4 cos θ < cos θ < 4
HITACHI 液晶プロジェクター CP-EX301NJ/CP-EW301NJ 取扱説明書 -詳細版- 【技術情報編】 日本語
A B C D E F G H I 1 3 5 7 9 11 13 15 17 19 2 4 6 8 10 12 14 16 18 K L J Y CB/PB CR/PR COMPONENT VIDEO OUT RS-232C RS-232C RS-232C Cable (cross) LAN cable (CAT-5 or greater) LAN LAN LAN LAN RS-232C BE
2つの疑問
Daiichi College of Pharmaceutical Sciences 22-1 Tamagawa-cho, Minami-ku,Fukuoka 815-8511, Japan 1. B 10 14 2 2. 1. 2. 3. G. Edelman 3. H (heavy chain) L (light chain) 2 4 S-S R. Porter papain) N Fab(Fragment
Nikon SB-800 使用説明書
Jp SB-800 2! $ ' $ % & " " " " " 3 ' ( # # # # # # & " " "! " " # ' # $ # " " " " " 4 " " " " ( # " " " " 5 6 " " " " # # # ( $ " " " 7 " " " " " " " # # # ( $ ' 8 9 k k k k k k k k k k u 10 k k k k k
0 (18) /12/13 (19) n Z (n Z ) 5 30 (5 30 ) (mod 5) (20) ( ) (12, 8) = 4
0 http://homepage3.nifty.com/yakuikei (18) 1 99 3 2014/12/13 (19) 1 100 3 n Z (n Z ) 5 30 (5 30 ) 37 22 (mod 5) (20) 201 300 3 (37 22 5 ) (12, 8) = 4 (21) 16! 2 (12 8 4) (22) (3 n )! 3 (23) 100! 0 1 (1)
０４年度LS民法Ⅰ教材改訂版.PDF
?? A AB A B C AB A B A B A B A A B A 98 A B A B A B A B B A A B AB AB A B A BB A B A B A B A B A B A AB A B B A B AB A A C AB A C A A B A B B A B A B B A B A B B A B A B A B A B A B A B A B
dynamics-solution2.dvi
1 1. (1) a + b = i +3i + k () a b =5i 5j +3k (3) a b =1 (4) a b = 7i j +1k. a = 14 l =/ 14, m=1/ 14, n=3/ 14 3. 4. 5. df (t) d [a(t)e(t)] =ti +9t j +4k, = d a(t) d[a(t)e(t)] e(t)+ da(t) d f (t) =i +18tj
PROSTAGE［プロステージ］
PROSTAGE & L 2 3200 650 2078 Storage system Panel system 3 esk system 2 250 22 01 125 1 2013-2014 esk System 2 L4OA V 01 2 L V L V OA 4 3240 32 2 7 4 OA P202 MG55 MG57 MG56 MJ58 MG45 MG55 MB95 Z712 MG57
総研大恒星進化概要.dvi
The Structure and Evolution of Stars I. Basic Equations. M r r =4πr2 ρ () P r = GM rρ. r 2 (2) r: M r : P and ρ: G: M r Lagrange r = M r 4πr 2 rho ( ) P = GM r M r 4πr. 4 (2 ) s(ρ, P ) s(ρ, P ) r L r T
第86回日本感染症学会総会学術集会後抄録（I）
κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β
HITACHI 液晶プロジェクター CP-AX3505J/CP-AW3005J 取扱説明書 -詳細版- 【技術情報編】
B A C E D 1 3 5 7 9 11 13 15 17 19 2 4 6 8 10 12 14 16 18 H G I F J M N L K Y CB/PB CR/PR COMPONENT VIDEO OUT RS-232C LAN RS-232C LAN LAN BE EF 03 06 00 2A D3 01 00 00 60 00 00 BE EF 03 06 00 BA D2 01
2016 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 1 16 2 1 () X O 3 (O1) X O, O (O2) O O (O3) O O O X (X, O) O X X (O1), (O2), (O3) (O2) (O3) n (O2) U 1,..., U n O U k O k=1 (O3) U λ O( λ Λ) λ Λ U λ O 0 X 0 (O2) n =
RN201602_cs5_0122.indd
ISSN 1349-1229 No.416 February 2016 2 SPECIAL TOPIC113 SPECIAL TOPIC 113 FACE Mykinso 113 SPECIAL TOPIC IUPAC 11320151231 RI RIBFRILAC 20039Zn30 Bi83 20047113 20054201283 113 1133 Bh107 20082009 113 113
I II
I II I I 8 I I 5 I 5 9 I 6 6 I 7 7 I 8 87 I 9 96 I 7 I 8 I 9 I 7 I 95 I 5 I 6 II 7 6 II 8 II 9 59 II 67 II 76 II II 9 II 8 II 5 8 II 6 58 II 7 6 II 8 8 I.., < b, b, c, k, m. k + m + c + c b + k + m log
70 : 20 : A B (20 ) (30 ) 50 1
70 : 0 : A B (0 ) (30 ) 50 1 1 4 1.1................................................ 5 1. A............................................... 6 1.3 B............................................... 7 8.1 A...............................................
ad bc A A A = ad bc ( d ) b c a n A n A n A A det A A ( ) a b A = c d det A = ad bc σ {,,,, n} {,,, } {,,, } {,,, } ( ) σ = σ() = σ() = n sign σ sign(
I n n A AX = I, YA = I () n XY A () X = IX = (YA)X = Y(AX) = YI = Y X Y () XY A A AB AB BA (AB)(B A ) = A(BB )A = AA = I (BA)(A B ) = B(AA )B = BB = I (AB) = B A (BA) = A B A B A = B = 5 5 A B AB BA A
G3 北 G4 北 G4 南エリアの堰内容量について G3 北 G4 北 G4 南エリアについては 外周堰を共有する構造であり 堰内容量 ( 想定漏えい量 ) は 3 エリア分として考慮している G4 南エリアのフランジタンク解体に伴い 3 エリア共通の外周堰の一部 (G4 南エリア部分 ) につい
G3 北 G4 北 G3 西エリアの堰内容量変更について 2018/05/17 G3 北 G4 北 G4 南エリアの堰内容量について G3 北 G4 北 G4 南エリアについては 外周堰を共有する構造であり 堰内容量 ( 想定漏えい量 ) は 3 エリア分として考慮している G4 南エリアのフランジタンク解体に伴い 3 エリア共通の外周堰の一部 (G4 南エリア部分 ) についても解体する計画である
untitled
20 3 Copyright (2007) by P.W.R.I. All rights reserved. No part of this book may be reproduced by any means, nor transmitted, nor translated into a machine language without the written permission of the
_19MY_FPACE
JAGUAR F- PACE PECIFICATION AND PRICE GUIDE ELECT PACK GRADE/ENGINE/PRICE F-PACE JAGUAR F-PACE P Nm F-PACE 047AB 81,000 8AT 180 430 6,560,000 6,074,075 21,750 21,880 LED DRL 064GJ 86,000 250P 8AT 250 365
20 9 19 1 3 11 1 3 111 3 112 1 4 12 6 121 6 122 7 13 7 131 8 132 10 133 10 134 12 14 13 141 13 142 13 143 15 144 16 145 17 15 19 151 1 19 152 20 2 21 21 21 211 21 212 1 23 213 1 23 214 25 215 31 22 33
免疫学研究のための製品群
ver.1.4 The path to new discoveries From basic to clinical research in immunology Good research starts with happy cells. gentlemacs TM Octo Dissociator with Heaters TM Whole Blood MicroBeads 37 RNA Option
τ τ
1 1 1.1 1.1.1 τ τ 2 1 1.1.2 1.1 1.1 µ ν M φ ν end ξ µ ν end ψ ψ = µ + ν end φ ν = 1 2 (µφ + ν end) ξ = ν (µ + ν end ) + 1 1.1 3 6.18 a b 1.2 a b 1.1.3 1.1.3.1 f R{A f } A f 1 B R{AB f 1 } COOH A OH B 1.3
(2016 2Q H) [ ] R 2 2 P = (a, b), Q = (c, d) Q P QP = ( ) a c b d (a c, b d) P = (a, b) O P ( ) a p = b P = (a, b) p = ( ) a b R 2 {( ) } R 2 x = x, y
![(2016 2Q H) [ ] R 2 2 P = (a, b), Q = (c, d) Q P QP = ( ) a c b d (a c, b d) P = (a, b) O P ( ) a p = b P = (a, b) p = ( ) a b R 2 {( ) } R 2 x = x, y](/thumbs/98/136512264.jpg "(2016 2Q H) [ ] R 2 2 P = (a, b), Q = (c, d) Q P QP = ( ) a c b d (a c, b d) P = (a, b) O P ( ) a p = b P = (a, b) p = ( ) a b R 2 {( ) } R 2 x = x, y")
(2016 2Q H) [ ] R 2 2 P = (a, b), Q = (c, d) Q P QP = a c b d (a c, b d) P = (a, b) O P a p = b P = (a, b) p = a b R 2 { } R 2 x = x, y R y 2 a p =, c q = b d p + a + c q = b + d q p P q a p = c R c b
TOPCON ブラント 保守部品満了履歴 トプコンサービス 保守部品供給終了年月 保守部品供給終了年月 機種名 ( 国内 ) 備 考 機種名 ( 国内 ) 電子 一般 電子 一般 AG シリース 年 3 月 DL-103 シリース 2014 年 3 月 2014 年 3 月 AG-20
保守部品供給終了年月 保守部品供給終了年月 電子 一般 電子 一般 AG シリース - 1993 年 3 月 DL-103 シリース 2014 年 3 月 2014 年 3 月 AG-20/30 シリース - 1995 年 3 月 DL-103A/AF 2014 年 3 月 2014 年 3 月 AG-20B/30B - 2002 年 3 月 DL-103R/RS 2014 年 3 月 2014 年
K E N Z U 2012 7 16 HP M. 1 1 4 1.1 3.......................... 4 1.2................................... 4 1.2.1..................................... 4 1.2.2.................................... 5................................
limit&derivative
- - 7 )................................................................................ 5.................................. 7.. e ).......................... 9 )..........................................
l µ l µ l 0 (1, x r, y r, z r ) 1 r (1, x r, y r, z r ) l µ g µν η µν 2ml µ l ν 1 2m r 2mx r 2 2my r 2 2mz r 2 2mx r 2 1 2mx2 2mxy 2mxz 2my r 2mz 2 r
2 1 (7a)(7b) λ i( w w ) + [ w + w ] 1 + w w l 2 0 Re(γ) α (7a)(7b) 2 γ 0, ( w) 2 1, w 1 γ (1) l µ, λ j γ l 2 0 Re(γ) α, λ w + w i( w w ) 1 + w w γ γ 1 w 1 r [x2 + y 2 + z 2 ] 1/2 ( w) 2 x2 + y 2 + z 2
Velar_19.5MY_オプション価格表_042802
RANGE ROVER PECIFICATION AND PRICE GUIDE ELECT PACK MODEL/GRADE/ENGINE/PRICE ELECT PACK MODEL/GRADE/ENGINE/PRICE RANGE ROVER RANGE ROVER ELECT PACK RANGE ROVER P Nm 8 10 & 047AB 070BA 300AQ 300AW 049AP
2.1: n = N/V ( ) k F = ( 3π 2 N ) 1/3 = ( 3π 2 n ) 1/3 V (2.5) [ ] a = h2 2m k2 F h2 2ma (1 27 ) (1 8 ) erg, (2.6) /k B 1 11 / K
![2.1: n = N/V ( ) k F = ( 3π 2 N ) 1/3 = ( 3π 2 n ) 1/3 V (2.5) [ ] a = h2 2m k2 F h2 2ma (1 27 ) (1 8 ) erg, (2.6) /k B 1 11 / K](/thumbs/86/94275608.jpg "2.1: n = N/V ( ) k F = ( 3π 2 N ) 1/3 = ( 3π 2 n ) 1/3 V (2.5) [ ] a = h2 2m k2 F h2 2ma (1 27 ) (1 8 ) erg, (2.6) /k B 1 11 / K")
2 2.1? [ ] L 1 ε(p) = 1 ( p 2 2m x + p 2 y + pz) 2 = h2 ( k 2 2m x + ky 2 + kz) 2 n x, n y, n z (2.1) (2.2) p = hk = h 2π L (n x, n y, n z ) (2.3) n k p 1 i (ε i ε i+1 )1 1 g = 2S + 1 2 1/2 g = 2 ( p F
381
P381 P386 P396 P397 P401 P423 P430 P433 P435 P437 P448 P451 P452 381 382 383 384 385 3.0mm 5.0mm 3.0mm 5.0mm SK SK3.0mm SK5.0mm 3.0mm PUR PUR3.0mm 2.0mm 2.0mm3.0mm 2.5mm 2.5mm3.0mm 3.0mm 5.0mm 3.0mm 1.8mm
_0212_68<5A66><4EBA><79D1>_<6821><4E86><FF08><30C8><30F3><30DC><306A><3057><FF09>.pdf
DVIOUT-HYOU
() P. () AB () AB ³ ³, BA, BA ³ ³ P. A B B A IA (B B)A B (BA) B A ³, A ³ ³ B ³ ³ x z ³ A AA w ³ AA ³ x z ³ x + z +w ³ w x + z +w ½ x + ½ z +w x + z +w x,,z,w ³ A ³ AA I x,, z, w ³ A ³ ³ + + A ³ A A P.
G A A G A G 4 1 1 2 3 4 5 6 7 110119118 b A G C G 4 1 7 * G A C b a HIKJ K J L f B c K c d e G 7 1 G 1 aa L M G L H G G 4 aa c c A a CB B A G f c C A G f G 9 8 1 2 c c G A A A f 1 13
) a + b = i + 6 b c = 6i j ) a = 0 b = c = 0 ) â = i + j 0 ˆb = 4) a b = b c = j + ) cos α = cos β = 6) a ˆb = b ĉ = 0 7) a b = 6i j b c = i + 6j + 8)
4 4 ) a + b = i + 6 b c = 6i j ) a = 0 b = c = 0 ) â = i + j 0 ˆb = 4) a b = b c = j + ) cos α = cos β = 6) a ˆb = b ĉ = 0 7) a b = 6i j b c = i + 6j + 8) a b a b = 6i j 4 b c b c 9) a b = 4 a b) c = 7
MS-1J/MS-1WJ（形名：MS-1/MS-1W）取扱説明書 - 詳細- 技術情報編
720 x 400 37.9 85.0 VESA TEXT 640 x 480 31.5 59.9 VESA VGA (60Hz) 640 x 480 37.9 72.8 VESA VGA (72Hz) 640 x 480 37.5 75.0 VESA VGA (75Hz) 640 x 480 43.3 85.0 VESA VGA (85Hz) 800 x 600 35.2 56.3 VESA SVGA
II 2 3.,, A(B + C) = AB + AC, (A + B)C = AC + BC. 4. m m A, m m B,, m m B, AB = BA, A,, I. 5. m m A, m n B, AB = B, A I E, 4 4 I, J, K
II. () 7 F 7 = { 0,, 2, 3, 4, 5, 6 }., F 7 a, b F 7, a b, F 7,. (a) a, b,,. (b) 7., 4 5 = 20 = 2 7 + 6, 4 5 = 6 F 7., F 7,., 0 a F 7, ab = F 7 b F 7. (2) 7, 6 F 6 = { 0,, 2, 3, 4, 5 },,., F 6., 0 0 a F
8.1 Fubini 8.2 Fubini 9 (0%) 10 (50%) Carathéodory 10.3 Fubini 1 Introduction 1 (1) (2) {f n (x)} n=1 [a, b] K > 0 n, x f n (x) K < ( ) x [a
![8.1 Fubini 8.2 Fubini 9 (0%) 10 (50%) Carathéodory 10.3 Fubini 1 Introduction 1 (1) (2) {f n (x)} n=1 [a, b] K > 0 n, x f n (x) K < ( ) x [a](/thumbs/92/108011076.jpg "8.1 Fubini 8.2 Fubini 9 (0%) 10 (50%) Carathéodory 10.3 Fubini 1 Introduction 1 (1) (2) {f n (x)} n=1 [a, b] K > 0 n, x f n (x) K < ( ) x [a")
% 100% 1 Introduction 2 (100%) 2.1 2.2 2.3 3 (100%) 3.1 3.2 σ- 4 (100%) 4.1 4.2 5 (100%) 5.1 5.2 5.3 6 (100%) 7 (40%) 8 Fubini (90%) 2007.11.5 1 8.1 Fubini 8.2 Fubini 9 (0%) 10 (50%) 10.1 10.2 Carathéodory
[RP13]シリーズカタログ
![[RP13]シリーズカタログ](/thumbs/99/140027433.jpg "[RP13]シリーズカタログ")
131520 : : : 2AAWG#24 : 2AAWG#22 1315 : AC30VDC42V 20 : AC100VDC140V 1. 1315 : 15m 20 : 30m DC1A -10 ~ +60-10 ~ +60 2. 1000M DC250V 3. AC300V1 4. 10s 10~55Hz/0.75mm 32 5. 10s 490m/s 2 11ms33 6. 7. 1315